BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis. N Engl J Med 1996;334:693-700. [DOI: 10.1056/nejm199603143341104] [Cited by in Crossref: 4631] [Cited by in F6Publishing: 1325] [Article Influence: 185.2] [Reference Citation Analysis]
Number Citing Articles
1 Lozanovski VJ, Kerr LTB, Khajeh E, Ghamarnejad O, Pfeiffenberger J, Hoffmann K, Chang DH, Mieth M, Longerich T, Strobel O, Weiss KH, Büchler MW, Mehrabi A. Liver Grafts with Major Extended Donor Criteria May Expand the Organ Pool for Patients with Hepatocellular Carcinoma. J Clin Med 2019;8:E1692. [PMID: 31618968 DOI: 10.3390/jcm8101692] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Shrum B, Costello P, McDonald W, Howlett C, Donnelly M, McAlister VC. In vitro three dimensional culture of hepatocellular carcinoma to measure prognosis and responsiveness to chemotherapeutic agents. Hepatobiliary Surg Nutr 2016;5:204-8. [PMID: 27275461 DOI: 10.21037/hbsn.2016.01.01] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Peta V, Zhu J, Lubman DM, Huguet S, Imbert-Bismutd F, Bolbach G, Clodic G, Matheron L, Ngo Y, Raluca P, Housset C, Rezai K, Poynard T; FibroFrance-Groupe Hospitalier Pitié Salpêtrière (GHPS) Group. Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease. Clin Res Hepatol Gastroenterol 2020;44:681-91. [PMID: 31964615 DOI: 10.1016/j.clinre.2019.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Kitai S, Kudo M, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M; Liver Cancer Study Group of Japan. Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis. Liver Cancer 2016;5:175-89. [PMID: 27493893 DOI: 10.1159/000367765] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
5 Zhong NB, Lv GM, Chen ZH. Stereotactic body radiotherapy combined with transarterial chemoembolization for huge (≥10 cm) hepatocellular carcinomas: A clinical study. Mol Clin Oncol 2014;2:839-44. [PMID: 25054055 DOI: 10.3892/mco.2014.304] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
6 Robbins AS, Daily MF, Aoki CA, Chen MS Jr, Troppmann C, Perez RV. Decreasing disparity in liver transplantation among white and Asian patients with hepatocellular carcinoma: California, 1998-2005. Cancer. 2008;113:2173-2179. [PMID: 18792066 DOI: 10.1002/cncr.23766] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
7 Rodríguez-Castro KI, De Martin E, Gambato M, Lazzaro S, Villa E, Burra P. Female gender in the setting of liver transplantation. World J Transplant. 2014;4:229-242. [PMID: 25540733 DOI: 10.5500/wjt.v4.i4.229] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
8 Sugimachi K, Matsumura T, Hirata H, Uchi R, Ueda M, Ueo H, Shinden Y, Iguchi T, Eguchi H, Shirabe K, Ochiya T, Maehara Y, Mimori K. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer. 2015;112:532-538. [PMID: 25584485 DOI: 10.1038/bjc.2014.621] [Cited by in Crossref: 171] [Cited by in F6Publishing: 152] [Article Influence: 28.5] [Reference Citation Analysis]
9 Memon K, Kulik L, Lewandowski RJ, Wang E, Ryu RK, Riaz A, Nikolaidis P, Miller FH, Yaghmai V, Baker T, Abecassis M, Benson AB, Mulcahy MF, Omary RA, Salem R. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J Hepatol. 2012;56:1112-1120. [PMID: 22245905 DOI: 10.1016/j.jhep.2011.11.020] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 6.8] [Reference Citation Analysis]
10 Mehta N. Hepatocellular Carcinoma-How to Determine Therapeutic Options. Hepatol Commun 2020;4:342-54. [PMID: 32140653 DOI: 10.1002/hep4.1481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
11 Ren Q, Fu S, Wang D, Ju W, He X. Prognostic Value of Preoperative Serum Leucine Aminopeptidases in Hepatocellular Carcinoma Patients Who Underwent Liver Transplantation. Cancer Manag Res 2021;13:1053-66. [PMID: 33574703 DOI: 10.2147/CMAR.S292128] [Reference Citation Analysis]
12 Pecchi A, Besutti G, De Santis M, Del Giovane C, Nosseir S, Tarantino G, Di Benedetto F, Torricelli P. Post-transplantation hepatocellular carcinoma recurrence: Patterns and relation between vascularity and differentiation degree. World J Hepatol. 2015;7:276-284. [PMID: 25729483 DOI: 10.4254/wjh.v7.i2.276] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
13 Tateyama M, Naoe H, Tanaka M, Tanaka K, Narahara S, Tokunaga T, Kawasaki T, Yoshimaru Y, Nagaoka K, Watanabe T, Setoyama H, Sasaki Y, Tanaka Y. Loss of skeletal muscle mass affects the incidence of minimal hepatic encephalopathy: a case control study. BMC Gastroenterol 2020;20:371. [PMID: 33167879 DOI: 10.1186/s12876-020-01501-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
14 Togashi J, Akamastu N, Kokudo N. Living donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital. Hepatobiliary Surg Nutr. 2016;5:399-407. [PMID: 27826554 DOI: 10.21037/hbsn.2016.08.05] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
15 Singal AG, Mukherjee A, Elmunzer BJ, Higgins PD, Lok AS, Zhu J, Marrero JA, Waljee AK. Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma. Am J Gastroenterol 2013;108:1723-30. [PMID: 24169273 DOI: 10.1038/ajg.2013.332] [Cited by in Crossref: 106] [Cited by in F6Publishing: 82] [Article Influence: 13.3] [Reference Citation Analysis]
16 Russo FP, Ferrarese A, Zanetto A. Recent advances in understanding and managing liver transplantation. F1000Res. 2016;5. [PMID: 28105300 DOI: 10.12688/f1000research.8768.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
17 Pascual S, Herrera I, Irurzun J. New advances in hepatocellular carcinoma. World J Hepatol. 2016;8:421-438. [PMID: 27028578 DOI: 10.4254/wjh.v8.i9.421] [Cited by in Crossref: 81] [Cited by in F6Publishing: 66] [Article Influence: 16.2] [Reference Citation Analysis]
18 Chen H, Miao R, Fan J, Han Z, Wu J, Qiu G, Tang H, Peng Z. Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma. Clin Exp Metastasis 2013;30:651-8. [PMID: 23378255 DOI: 10.1007/s10585-013-9569-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
19 Massani M, Stecca T, Ruffolo C, Bassi N. Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis. Updates Surg 2017;69:67-73. [PMID: 28097502 DOI: 10.1007/s13304-017-0414-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
20 Tan DJH, Wong C, Ng CH, Poh CW, Jain SR, Huang DQ, Muthiah MD. A Meta-Analysis on the Rate of Hepatocellular Carcinoma Recurrence after Liver Transplant and Associations to Etiology, Alpha-Fetoprotein, Income and Ethnicity. J Clin Med 2021;10:E238. [PMID: 33440759 DOI: 10.3390/jcm10020238] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Tapia-Abellán A, Martínez-Esparza M, Ruiz-Alcaraz AJ, Hernández-Caselles T, Martínez-Pascual C, Miras-López M, Such J, Francés R, García-Peñarrubia P. The peritoneal macrophage inflammatory profile in cirrhosis depends on the alcoholic or hepatitis C viral etiology and is related to ERK phosphorylation. BMC Immunol 2012;13:42. [PMID: 22866973 DOI: 10.1186/1471-2172-13-42] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
22 Filgueira NA. Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation. World J Hepatol 2019;11:261-72. [PMID: 30967904 DOI: 10.4254/wjh.v11.i3.261] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
23 Huang K, Dong Z, Cai H, Huang M, Peng Z, Xu L, Jia Y, Song C, Li ZP, Feng ST. Imaging biomarkers for well and moderate hepatocellular carcinoma: preoperative magnetic resonance image and histopathological correlation. BMC Cancer 2019;19:364. [PMID: 30999947 DOI: 10.1186/s12885-019-5574-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
24 Lee WC, Wu TH, Wang YC, Cheng CH, Lee CF, Wu TJ, Chou HS, Chan KM, Lee CS. Renal Function Improvement by Telbivudine in Liver Transplant Recipients with Chronic Kidney Disease. Biomed Res Int 2017;2017:9324310. [PMID: 28884132 DOI: 10.1155/2017/9324310] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
25 Riley TR, Smith JP. Preventive care in chronic liver disease. J Gen Intern Med 1999;14:699-704. [PMID: 10571719 DOI: 10.1046/j.1525-1497.1999.11188.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
26 Sawada T, Kubota K, Kita J, Kato M, Shiraki T, Park K, Shimoda M. Clinical outcome of hepatectomy for hepatocellular carcinomas≤2 cm. World J Surg 2011;35:377-85. [PMID: 21042908 DOI: 10.1007/s00268-010-0851-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
27 Affonso BB, Galastri FL, da Motta Leal Filho JM, Nasser F, Falsarella PM, Cavalcante RN, de Almeida MD, Felga GEG, Valle LGM, Wolosker N. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging. World J Gastroenterol 2019;25:5687-701. [PMID: 31602168 DOI: 10.3748/wjg.v25.i37.5687] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
28 Xu H, Deng Y, Zhou Z, Huang Y. Chinese Herbal Medicine (Chaihu-Huaji Decoction) Alleviates Postembolization Syndrome following Transcatheter Arterial Chemoembolization and Improves Survival in Unresectable Hepatocellular Cancer: A Retrospective Study. Evid Based Complement Alternat Med 2019;2019:6269518. [PMID: 30854013 DOI: 10.1155/2019/6269518] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Braat AJ, Huijbregts JE, Molenaar IQ, Borel Rinkes IH, van den Bosch MA, Lam MG. Hepatic radioembolization as a bridge to liver surgery. Front Oncol. 2014;4:199. [PMID: 25126539 DOI: 10.3389/fonc.2014.00199] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
30 Abu-Hilal M, Primrose JN, Casaril A, McPhail MJ, Pearce NW, Nicoli N. Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. J Gastrointest Surg. 2008;12:1521-1526. [PMID: 18592325 DOI: 10.1007/s11605-008-0553-4] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 5.5] [Reference Citation Analysis]
31 Woodrell CD, Hansen L, Schiano TD, Goldstein NE. Palliative Care for People With Hepatocellular Carcinoma, and Specific Benefits for Older Adults. Clin Ther 2018;40:512-25. [PMID: 29571567 DOI: 10.1016/j.clinthera.2018.02.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
32 Garg R, Foley K, Movahedi B, Masciocchi MJ, Bledsoe JR, Ding L, Rava P, Fitzgerald TJ, Sioshansi S. Outcomes After Stereotactic Body Radiation Therapy as a Bridging Modality to Liver Transplantation for Hepatocellular Carcinoma. Adv Radiat Oncol 2021;6:100559. [PMID: 33665482 DOI: 10.1016/j.adro.2020.08.016] [Reference Citation Analysis]
33 Lanaya H, Natarajan A, Komposch K, Li L, Amberg N, Chen L, Wculek SK, Hammer M, Zenz R, Peck-Radosavljevic M. EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol. 2014;16:972-977. [PMID: 25173978 DOI: 10.1038/ncb3031] [Cited by in Crossref: 136] [Cited by in F6Publishing: 125] [Article Influence: 19.4] [Reference Citation Analysis]
34 Nakagawa H, Maeda S. Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK. Patholog Res Int 2012;2012:172894. [PMID: 22666632 DOI: 10.1155/2012/172894] [Cited by in Crossref: 33] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
35 Urrunaga NH, Singal AG, Cuthbert JA, Rockey DC. Hemorrhagic ascites. Clinical presentation and outcomes in patients with cirrhosis. J Hepatol. 2013;58:1113-1118. [PMID: 23348236 DOI: 10.1016/j.jhep.2013.01.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
36 Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg. 2007;245:51-58. [PMID: 17197965 DOI: 10.1097/01.sla.] [Reference Citation Analysis]
37 Fan J, Yang G, Fu Z, Peng Z, Xia Q, Peng C, Qian J, Zhou J, Xu Y, Qiu S, Zhong L, Zhou G, Zhang J. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. J Cancer Res Clin Oncol 2009;135:1403-12. [DOI: 10.1007/s00432-009-0584-6] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 5.2] [Reference Citation Analysis]
38 Kim SH, Kamaya A, Willmann JK. CT perfusion of the liver: principles and applications in oncology. Radiology. 2014;272:322-344. [PMID: 25058132 DOI: 10.1148/radiol.14130091] [Cited by in Crossref: 109] [Cited by in F6Publishing: 67] [Article Influence: 15.6] [Reference Citation Analysis]
39 Lausch A, Sinclair K, Lock M, Fisher B, Jensen N, Gaede S, Chen J, Wong E. Determination and comparison of radiotherapy dose responses for hepatocellular carcinoma and metastatic colorectal liver tumours. Br J Radiol 2013;86:20130147. [PMID: 23690438 DOI: 10.1259/bjr.20130147] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
40 Lai Q, Vitale A, Halazun K, Iesari S, Viveiros A, Bhangui P, Mennini G, Wong T, Uemoto S, Lin CC, Mittler J, Ikegami T, Zhe Y, Zheng SS, Soejima Y, Hoppe-Lotichius M, Chen CL, Kaido T, Lo CM, Rossi M, Soin AS, Finkenstedt A, Emond JC, Cillo U, Lerut J. Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort. Cancers (Basel) 2020;12:E452. [PMID: 32075133 DOI: 10.3390/cancers12020452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
41 Zhu Z. Milan criteria and its expansions in liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr 2016;5:498-502. [PMID: 28124007 DOI: 10.21037/hbsn.2016.12.09] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Giannini EG, Cucchetti A, Erroi V, Garuti F, Odaldi F, Trevisani F. Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it? World J Gastroenterol. 2013;19:8808-8821. [PMID: 24379604 DOI: 10.3748/wjg.v19.i47.8808] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 35] [Article Influence: 6.6] [Reference Citation Analysis]
43 Chen LP, Li C, Wen TF, Yan LN, Li B, Yang JY. Can living donor liver transplantation offer similar outcomes to deceased donor liver transplantation using expanded selection criteria for hepatocellular carcinoma? Pak J Med Sci 2015;31:763-9. [PMID: 26430399 DOI: 10.12669/pjms.314.7523] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
44 Wang Z, Yang G, Nie P, Fu J, Wang X, Liu D. Dynamical observation on biological progression of VX2 liver tumors to identify the optimal time for intervention in animal models. PLoS One 2013;8:e74327. [PMID: 23977399 DOI: 10.1371/journal.pone.0074327] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
45 Colombo M. Natural history of hepatocellular carcinoma. Cancer Imaging 2005;5:85-8. [PMID: 16154825 DOI: 10.1102/1470-7330.2005.0014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
46 Freitas AC, Shiguihara RS, Monteiro RT, Pazeto TL, Coelho JC. COMPARATIVE STUDY ON LIVER TRANSPLANTATION WITH AND WITHOUT HEPATOCELLULAR CARCINOMA WITH CIRRHOSIS: ANALYSIS OF MELD, WAITING TIME AND SURVIVAL. Arq Bras Cir Dig 2016;29:21-5. [PMID: 27120734 DOI: 10.1590/0102-6720201600010006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
47 Buscarini E, Savoia A, Brambilla G, Menozzi F, Reduzzi L, Strobel D, Hänsler J, Buscarini L, Gaiti L, Zambelli A. Radiofrequency thermal ablation of liver tumors. Eur Radiol. 2005;15:884-894. [PMID: 15754165 DOI: 10.1007/s00330-005-2652-x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
48 Park MS, Lee KW, Yi NJ, Choi YR, Kim H, Hong G, Suh KS, Kwon CH, Joh JW, Lee SK. Optimal tailored screening protocol after living donor liver transplantation for hepatocellular carcinoma. J Korean Med Sci 2014;29:1360-6. [PMID: 25368488 DOI: 10.3346/jkms.2014.29.10.1360] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
49 Levi Sandri GB, Ettorre GM, Giannelli V, Colasanti M, Sciuto R, Pizzi G, Cianni R, D'Offizi G, Antonini M, Vennarecci G, Lucatelli P. Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review. Transl Gastroenterol Hepatol 2017;2:98. [PMID: 29264436 DOI: 10.21037/tgh.2017.11.11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
50 Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000;46:2050-68. [PMID: 11106350 [PMID: 11106350 DOI: 10.1093/clinchem/46.12.2050] [Cited by in Crossref: 213] [Cited by in F6Publishing: 95] [Article Influence: 10.7] [Reference Citation Analysis]
51 Cai E, Song X, Han M, Yang L, Zhao Y, Li W, Han J, Tu S. Experimental study of the anti-tumour activity and pharmacokinetics of arctigenin and its valine ester derivative. Sci Rep 2018;8:3307. [PMID: 29459629 DOI: 10.1038/s41598-018-21722-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
52 Tanaka K, Ogura Y, Kiuchi T, Inomata Y, Uemoto S, Furukawa H. Living donor liver transplantation: Eastern experiences. HPB (Oxford). 2004;6:88-94. [PMID: 18333056 DOI: 10.1080/13651820310020765] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
53 Jain A, Miller D, Schreibman I, Riley TR 3rd, Krok KL, Dohi T, Sharma R, Kadry Z. Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy? Hepatol Int 2019;13:190-8. [PMID: 30680672 DOI: 10.1007/s12072-019-09930-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Wei CY, Chen PC, Chau GY, Lee RC, Chen PH, Huo TI, Huang YH, Su YH, Hou MC, Wu JC, Su CW. Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. Ann Transl Med 2020;8:238. [PMID: 32309385 DOI: 10.21037/atm.2019.12.157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
55 Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 1999;229:216-22. [PMID: 10024103 DOI: 10.1097/00000658-199902000-00009] [Cited by in Crossref: 417] [Cited by in F6Publishing: 389] [Article Influence: 19.0] [Reference Citation Analysis]
56 Pawlik TM, Gleisner AL, Anders RA, Assumpcao L, Maley W, Choti MA. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg. 2007;245:435-442. [PMID: 17435551 DOI: 10.1097/01.sla.0000250420.73854.ad] [Cited by in Crossref: 145] [Cited by in F6Publishing: 126] [Article Influence: 10.4] [Reference Citation Analysis]
57 Sanoff HK, Chang Y, Reimers M, Lund JL. Hospice Utilization and Its Effect on Acute Care Needs at the End of Life in Medicare Beneficiaries With Hepatocellular Carcinoma. J Oncol Pract 2017;13:e197-206. [PMID: 28029300 DOI: 10.1200/JOP.2016.017814] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 5.6] [Reference Citation Analysis]
58 McGahan JP, Bishop J, Webb J, Howell L, Torok N, Lamba R, Corwin MT. Role of FNA and Core Biopsy of Primary and Metastatic Liver Disease. Int J Hepatol 2013;2013:174103. [PMID: 24369506 DOI: 10.1155/2013/174103] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
59 Boldrini L, Corradini S, Gani C, Henke L, Hosni A, Romano A, Dawson L. MR-Guided Radiotherapy for Liver Malignancies. Front Oncol 2021;11:616027. [PMID: 33869001 DOI: 10.3389/fonc.2021.616027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
60 Hsu CY, Liu PH, Ho SY, Huang YH, Lee YH, Chiou YY, Hsieh TH, Fang T, Tsai YJ, Hou MC, Huo TI. Impact of tumor burden on prognostic prediction for patients with terminal stage hepatocellular carcinoma: A nomogram study. PLoS One 2017;12:e0188031. [PMID: 29125877 DOI: 10.1371/journal.pone.0188031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
61 Hucke F, Sieghart W, Schöniger-Hekele M, Peck-Radosavljevic M, Müller C. Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program? Wien Klin Wochenschr. 2011;123:542-551. [PMID: 21800047 DOI: 10.1007/s00508-011-0033-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
62 Frangakis C, Geschwind JF, Kim D, Chen Y, Koteish A, Hong K, Liapi E, Georgiades CS. Chemoembolization decreases drop-off risk of hepatocellular carcinoma patients on the liver transplant list. Cardiovasc Intervent Radiol. 2011;34:1254-1261. [PMID: 21191590 DOI: 10.1007/s00270-010-0077-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
63 Somma F, Stoia V, Serra N, D'Angelo R, Gatta G, Fiore F. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival. PLoS One 2019;14:e0216935. [PMID: 31141552 DOI: 10.1371/journal.pone.0216935] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
64 Nobel YR, Goldberg DS. Variable Use of Model for End-Stage Liver Disease Exception Points in Patients With Neuroendocrine Tumors Metastatic to the Liver and Its Impact on Patient Outcomes. Transplantation 2015;99:2341-6. [PMID: 25989503 DOI: 10.1097/TP.0000000000000723] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
65 Hakamada K, Kimura N, Miura T, Morohashi H, Ishido K, Nara M, Toyoki Y, Narumi S, Sasaki M. Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma. World J Gastroenterol. 2008;14:1370-1377. [PMID: 18322950 DOI: 10.3748/wjg.14.1370] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
66 Bürger C, Maschmeier M, Hüsing-Kabar A, Wilms C, Köhler M, Schmidt M, Schmidt HH, Kabar I. Achieving Complete Remission of Hepatocellular Carcinoma: A Significant Predictor for Recurrence-Free Survival after Liver Transplantation. Can J Gastroenterol Hepatol 2019;2019:5796074. [PMID: 30729099 DOI: 10.1155/2019/5796074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Vitale A, Volk M, Cillo U. Transplant benefit for patients with hepatocellular carcinoma. World J Gastroenterol 2013;19:9183-8. [PMID: 24409046 DOI: 10.3748/wjg.v19.i48.9183] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
68 Yaprak O, Acar S, Ertugrul G, Dayangac M. Role of pre-transplant 18F-FDG PET/CT in predicting hepatocellular carcinoma recurrence after liver transplantation. World J Gastrointest Oncol 2018;10:336-43. [PMID: 30364796 DOI: 10.4251/wjgo.v10.i10.336] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
69 Ishii M, Mizuguchi T, Kawamoto M, Meguro M, Ota S, Nishidate T, Okita K, Kimura Y, Hui TT, Hirata K. Propensity score analysis demonstrated the prognostic advantage of anatomical liver resection in hepatocellular carcinoma. World J Gastroenterol 2014;20:3335-42. [PMID: 24696614 DOI: 10.3748/wjg.v20.i12.3335] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
70 Jun BG, Lee WC, Jang JY, Jeong SW, Chang Y, Lee SH, Kim YD, Kim SG, Cheon GJ, Kim YS, Kim HS, Jin SY. Relation of fibroblast growth factor receptor 2 expression to hepatocellular carcinoma recurrence after liver resection. PLoS One 2020;15:e0227440. [PMID: 31940413 DOI: 10.1371/journal.pone.0227440] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
71 Marcon PDS, Tovo CV, Kliemann DA, Fisch P, de Mattos AA. Incidence of hepatocellular carcinoma in patients with chronic liver disease due to hepatitis B or C and coinfected with the human immunodeficiency virus: A retrospective cohort study. World J Gastroenterol. 2018;24:613-622. [PMID: 29434450 DOI: 10.3748/wjg.v24.i5.613] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
72 Burra P, Rodriguez-Castro KI. Neoplastic disease after liver transplantation: Focus on de novo neoplasms. World J Gastroenterol. 2015;21:8753-8768. [PMID: 26269665 DOI: 10.3748/wjg.v21.i29.8753] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 28] [Article Influence: 8.2] [Reference Citation Analysis]
73 Kim B, Woreta T, Chen PH, Limketkai B, Singer A, Dagher N, Cameron A, Lin MT, Kamel I, Gurakar A. Donor-transmitted malignancy in a liver transplant recipient: a case report and review of literature. Dig Dis Sci. 2013;58:1185-1190. [PMID: 23242807 DOI: 10.1007/s10620-012-2501-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
74 Chaiteerakij R, Zhang X, Addissie BD, Mohamed EA, Harmsen WS, Theobald PJ, Peters BE, Balsanek JG, Ward MM, Giama NH, Moser CD, Oseini AM, Umeda N, Venkatesh S, Harnois DM, Charlton MR, Yamada H, Satomura S, Algeciras-Schimnich A, Snyder MR, Therneau TM, Roberts LR. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2015;21:599-606. [PMID: 25789635 DOI: 10.1002/lt.24117] [Cited by in Crossref: 52] [Cited by in F6Publishing: 40] [Article Influence: 10.4] [Reference Citation Analysis]
75 Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, Zahlten-Hinguranage A, Schirrmacher P, Schmidt J, Büchler MW. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer. 2008;8:349. [PMID: 19036146 DOI: 10.1186/1471-2407-8-349] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 5.5] [Reference Citation Analysis]
76 Kavanaugh G, Williams J, Morris AS, Nickels ML, Walker R, Koglin N, Stephens AW, Washington MK, Geevarghese SK, Liu Q, Ayers D, Shyr Y, Manning HC. Utility of [18F]FSPG PET to Image Hepatocellular Carcinoma: First Clinical Evaluation in a US Population. Mol Imaging Biol. 2016;18:924-934. [PMID: 27677886 DOI: 10.1007/s11307-016-1007-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
77 Tovoli F, Negrini G, Bolondi L. Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. Hepat Oncol 2016;3:119-36. [PMID: 30191033 DOI: 10.2217/hep-2015-0006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
78 Tapadar S, Fathi S, Wu B, Sun CQ, Raji I, Moore SG, Arnold RS, Gaul DA, Petros JA, Oyelere AK. Liver-Targeting Class I Selective Histone Deacetylase Inhibitors Potently Suppress Hepatocellular Tumor Growth as Standalone Agents. Cancers (Basel) 2020;12:E3095. [PMID: 33114147 DOI: 10.3390/cancers12113095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
79 Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, Kinkhabwala M, Ahmed MM, Vikram B, Coleman CN, Guha C. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. J Natl Cancer Inst. 2016;108. [PMID: 27377923 DOI: 10.1093/jnci/djw133] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
80 Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624. [PMID: 24691105 DOI: 10.1371/journal.pmed.1001624] [Cited by in Crossref: 364] [Cited by in F6Publishing: 307] [Article Influence: 52.0] [Reference Citation Analysis]
81 Alver SK, Lorenz DJ, Washburn K, Marvin MR, Brock GN. Comparison of two equivalent model for end-stage liver disease scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry. Transpl Int 2017;30:1098-109. [PMID: 28403575 DOI: 10.1111/tri.12967] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
82 Knechtle SJ. Challenging choices: liver transplantation for hepatocellular carcinoma. Ann Surg 2004;239:160-1. [PMID: 14745322 DOI: 10.1097/01.sla.0000109169.72607.50] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
83 Hu Z, Zhou J, Xu X, Li Z, Zhou L, Wu J, Zhang M, Zheng S. Salvage liver transplantation is a reasonable option for selected patients who have recurrent hepatocellular carcinoma after liver resection. PLoS One. 2012;7:e36587. [PMID: 22574187 DOI: 10.1371/journal.pone.0036587] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
84 Feng D, Wang M, Hu J, Li S, Zhao S, Li H, Liu L. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases. Ann Transl Med 2020;8:553. [PMID: 32411776 DOI: 10.21037/atm.2020.02.116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
85 Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg. 2003;238:703-710. [PMID: 14578733 DOI: 10.1097/01.sla.0000094549.11754.e6] [Cited by in Crossref: 311] [Cited by in F6Publishing: 280] [Article Influence: 17.3] [Reference Citation Analysis]
86 Toso C, Cader S, Mentha-Dugerdil A, Meeberg G, Majno P, Morard I, Giostra E, Berney T, Morel P, Mentha G, Kneteman NM. Factors predicting survival after post-transplant hepatocellular carcinoma recurrence. J Hepatobiliary Pancreat Sci 2013;20:342-7. [PMID: 22710887 DOI: 10.1007/s00534-012-0528-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
87 He T, Fong JN, Moore LW, Ezeana CF, Victor D, Divatia M, Vasquez M, Ghobrial RM, Wong STC. An imageomics and multi-network based deep learning model for risk assessment of liver transplantation for hepatocellular cancer. Comput Med Imaging Graph 2021;89:101894. [PMID: 33725579 DOI: 10.1016/j.compmedimag.2021.101894] [Reference Citation Analysis]
88 Brito AF, Abrantes AM, Tralhão JG, Botelho MF. Targeting Hepatocellular Carcinoma: What did we Discover so Far? Oncol Rev 2016;10:302. [PMID: 27994769 DOI: 10.4081/oncol.2016.302] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
89 Park C, Kim JH, Kim PH, Kim SY, Gwon DI, Chu HH, Park M, Hur J, Kim JY, Kim DJ. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Korean J Radiol 2021;22:213-24. [PMID: 32901464 DOI: 10.3348/kjr.2020.0325] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
90 Moon DB, Lee SG. Liver transplantation. Gut Liver. 2009;3:145-165. [PMID: 20431740 DOI: 10.5009/gnl.2009.3.3.145] [Cited by in Crossref: 54] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
91 Müller L, Stoehr F, Mähringer-Kunz A, Hahn F, Weinmann A, Kloeckner R. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. J Hepatocell Carcinoma 2021;8:403-19. [PMID: 34012930 DOI: 10.2147/JHC.S285735] [Reference Citation Analysis]
92 Chan A. Liver transplantation for unresectable colorectal liver metastasis. Hepatobiliary Surg Nutr 2013;2:162-4. [PMID: 24570935 DOI: 10.3978/j.issn.2304-3881.2013.05.01] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
93 Pan JJ, Javle M, Thinn MM, Hsueh CT, Hsueh CT. Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma. Hepat Med 2010;2:147-55. [PMID: 24367212 DOI: 10.2147/HMER.S7123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
94 Lingiah VA, Niazi M, Olivo R, Paterno F, Guarrera JV, Pyrsopoulos NT. Liver Transplantation Beyond Milan Criteria. J Clin Transl Hepatol 2020;8:69-75. [PMID: 32274347 DOI: 10.14218/JCTH.2019.00050] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
95 Hiraoka A, Kumagi T, Hirooka M, Uehara T, Kurose K, Iuchi H, Hiasa Y, Matsuura B, Michitaka K, Kumano S, Tanaka H, Yamashita Y, Horiike N, Mochizuki T, Onji M. Prognosis following transcatheter arterial embolization for 121 patients with unresectable hepatocellular carcinoma with or without a history of treatment. World J Gastroenterol 2006;12:2075-9. [PMID: 16610060 DOI: 10.3748/wjg.v12.i13.2075] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
96 Choti MA. Transplantation versus resection for hepatocellular carcinoma in the mild cirrhotic: framing the debate. J Gastrointest Surg. 2009;13:1021-1022. [PMID: 19333661 DOI: 10.1007/s11605-009-0868-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
97 Giannini EG, Moscatelli A, Pellegatta G, Vitale A, Farinati F, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Missale G, Foschi FG, Gasbarrini A, Baroni GS, Virdone R, Masotto A, Trevisani F; Italian Liver Cancer (ITA. LI.CA) Group; Italian Liver Cancer ITA LI CA Group. Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. Am J Gastroenterol. 2016;111:70-77. [PMID: 26729544 DOI: 10.1038/ajg.2015.389] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
98 Hiraoka A, Kato M, Marui K, Murakami T, Onishi K, Adachi T, Matsuoka J, Ueki H, Yoshino T, Tsuruta M, Aibiki T, Okudaira T, Kuroda T, Iwasaki R, Suga Y, Miyata H, Ninomiya T, Hirooka M, Abe M, Matsuura B, Michitaka K, Hiasa Y. Easy clinical predictor for low BCAA to tyrosine ratio in chronic liver disease patients with hepatocellular carcinoma: Usefulness of ALBI score as nutritional prognostic marker. Cancer Med 2021;10:3584-92. [PMID: 33960691 DOI: 10.1002/cam4.3908] [Reference Citation Analysis]
99 Iannicelli E, Di Pietropaolo M, Marignani M, Briani C, Federici GF, Delle Fave G, David V. Gadoxetic acid-enhanced MRI for hepatocellular carcinoma and hypointense nodule observed in the hepatobiliary phase. Radiol Med. 2014;119:367-376. [PMID: 24297598 DOI: 10.1007/s11547-013-0364-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
100 Hu Z, Zhou J, Wang H, Zhang M, Li S, Huang Y, Wu J, Li Z, Zhou L, Zheng S. Survival in liver transplant recipients with hepatitis B- or hepatitis C-associated hepatocellular carcinoma: the Chinese experience from 1999 to 2010. PLoS One. 2013;8:e61620. [PMID: 23613886 DOI: 10.1371/journal.pone.0061620] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
101 Attia KA, Ackoundou-N'guessan KC, N'dri-Yoman AT, Mahassadi AK, Messou E, Bathaix YF, Kissi YH. Child-Pugh-Turcott versus Meld score for predicting survival in a retrospective cohort of black African cirrhotic patients. World J Gastroenterol 2008;14:286-91. [PMID: 18186569 DOI: 10.3748/wjg.14.286] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
102 Zheng J, Chakraborty J, Chapman WC, Gerst S, Gonen M, Pak LM, Jarnagin WR, DeMatteo RP, Do RKG, Simpson AL; Hepatopancreatobiliary Service in the Department of Surgery of the Memorial Sloan Kettering Cancer Center., Research Staff in the Department of Surgery at Washington University School of Medicine. Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma Using Quantitative Image Analysis. J Am Coll Surg 2017;225:778-788.e1. [PMID: 28941728 DOI: 10.1016/j.jamcollsurg.2017.09.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
103 Allard MA, Sa Cunha A, Ruiz A, Vibert E, Sebagh M, Castaing D, Adam R. The postresection alpha-fetoprotein in cirrhotic patients with hepatocellular carcinoma. An independent predictor of outcome. J Gastrointest Surg. 2014;18:701-708. [PMID: 24402605 DOI: 10.1007/s11605-013-2433-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
104 Ogawa K, Takada Y. Living vs. deceased-donor liver transplantation for patients with hepatocellular carcinoma. Transl Gastroenterol Hepatol 2016;1:35. [PMID: 28138602 DOI: 10.21037/tgh.2016.04.03] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
105 Wu L, Yang F, Lin B, Chen X, Yin S, Zhang F, Xie H, Zhou L, Zheng S. MicroRNA-424 expression predicts tumor recurrence in patients with hepatocellular carcinoma following liver transplantation. Oncol Lett 2018;15:9126-32. [PMID: 29805644 DOI: 10.3892/ol.2018.8539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
106 Vidal RIO, Vidal EIO, Pereira BB, Assane CC, Ribeiro A, do Nascimento EM, Romeiro FG, Ribeiro Filho J. Risk Factors for Hepatocellular Carcinoma Recurrence and Survival after Liver Transplantation in Patients with HCV-Related Cirrhosis. Biomed Res Int 2020;2020:1487593. [PMID: 33134370 DOI: 10.1155/2020/1487593] [Reference Citation Analysis]
107 Vatansever S, Farajov R, Yılmaz HC, Zeytunlu M, Paköz ZB, Kılıç M. Hepatitis B and hepatocellular carcinoma recurrence after living donor liver transplantation: The role of the Milan criteria. Turk J Gastroenterol 2019;30:75-80. [PMID: 30644364 DOI: 10.5152/tjg.2018.18794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Kong L, Li M, Li L, Jiang L, Yang J, Yan L. Splenectomy before adult liver transplantation: a retrospective study. BMC Surg 2017;17:44. [PMID: 28427382 DOI: 10.1186/s12893-017-0243-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
109 Sharpton SR, Terrault NA, Posselt AM. Outcomes of Sleeve Gastrectomy in Obese Liver Transplant Candidates. Liver Transpl 2019;25:538-44. [PMID: 30588743 DOI: 10.1002/lt.25406] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
110 Chan SC. Liver transplantation for hepatocellular carcinoma. Liver Cancer 2013;2:338-44. [PMID: 24400221 DOI: 10.1159/000343849] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
111 Donadon M, Cimino M, Procopio F, Morenghi E, Montorsi M, Torzilli G. Potential role of cholinesterases to predict short-term outcome after hepatic resection for hepatocellular carcinoma. Updates Surg 2013;65:11-8. [PMID: 22911016 DOI: 10.1007/s13304-012-0174-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
112 Lubienski A, Simon M, Lubienski K, Gellissen J, Hoffmann R, Jakobs T, Helmberger T. Update Chemoperfusion und -embolisation. Radiologe 2007;47:1097-108. [DOI: 10.1007/s00117-007-1587-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
113 Wang Z, Liao J, Wu S, Li C, Fan J, Peng Z. Recipient C6 rs9200 genotype is associated with hepatocellular carcinoma recurrence after orthotopic liver transplantation in a Han Chinese population. Cancer Gene Ther 2016;23:157-61. [PMID: 27173880 DOI: 10.1038/cgt.2016.7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
114 Yoo EJ, Shin HS, Kim SU, Joo DJ, Park JY, Choi GH, Kim DY, Ahn SH, Seong J, Koh MJ, Han KH, Chon CY. Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. Onco Targets Ther 2013;6:755-9. [PMID: 23836988 DOI: 10.2147/OTT.S45602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
115 Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, Soulen MC, Geschwind JF, Kulik L, Kim YH, Spreafico C, Maccauro M, Bester L, Brown DB, Ryu RK, Sze DY, Rilling WS, Sato KT, Sangro B, Bilbao JI, Jakobs TF, Ezziddin S, Kulkarni S, Kulkarni A, Liu DM, Valenti D, Hilgard P, Antoch G, Muller SP, Alsuhaibani H, Mulcahy MF, Burrel M, Real MI, Spies S, Esmail AA, Raoul JL, Garin E, Johnson MS, Benson AB 3rd, Sharma RA, Wasan H, Lambert B, Memon K, Kennedy AS, Riaz A; Technology Assessment Committee., Interventional Oncology Task Force of the Society of Interventional Radiology. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol 2011;22:265-78. [PMID: 21353979 DOI: 10.1016/j.jvir.2010.10.029] [Cited by in Crossref: 148] [Cited by in F6Publishing: 129] [Article Influence: 14.8] [Reference Citation Analysis]
116 Hackl C, Schlitt HJ, Kirchner GI, Knoppke B, Loss M. Liver transplantation for malignancy: current treatment strategies and future perspectives. World J Gastroenterol. 2014;20:5331-5344. [PMID: 24833863 DOI: 10.3748/wjg.v20.i18.5331] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
117 Merchant N, David CS, Cunningham SC. Early Hepatocellular Carcinoma: Transplantation versus Resection: The Case for Liver Resection. Int J Hepatol 2011;2011:142085. [PMID: 21994848 DOI: 10.4061/2011/142085] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
118 Tateishi R, Matsumura T, Okanoue T, Shima T, Uchino K, Fujiwara N, Senokuchi T, Kon K, Sasako T, Taniai M, Kawaguchi T, Inoue H, Watada H, Kubota N, Shimano H, Kaneko S, Hashimoto E, Watanabe S, Shiota G, Ueki K, Kashiwabara K, Matsuyama Y, Tanaka H, Kasuga M, Araki E, Koike K; LUCID study investigators. Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. J Gastroenterol 2021;56:261-73. [PMID: 33427937 DOI: 10.1007/s00535-020-01754-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Rinninella E, Cerrito L, Spinelli I, Cintoni M, Mele MC, Pompili M, Gasbarrini A. Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. J Clin Transl Hepatol 2017;5:235-48. [PMID: 28936405 DOI: 10.14218/JCTH.2017.00002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
120 Burra P, Zanetto A, Germani G. Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma. Cancers (Basel) 2018;10:E46. [PMID: 29425151 DOI: 10.3390/cancers10020046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
121 Yokoo T, Patel AD, Lev-Cohain N, Singal AG, Yopp AC, Pedrosa I. Extrahepatic metastasis risk of hepatocellular carcinoma based on α-fetoprotein and tumor staging parameters at cross-sectional imaging. Cancer Manag Res 2017;9:503-11. [PMID: 29081671 DOI: 10.2147/CMAR.S147097] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
122 Santopaolo F, Lenci I, Milana M, Manzia TM, Baiocchi L. Liver transplantation for hepatocellular carcinoma: Where do we stand? World J Gastroenterol 2019;25:2591-602. [PMID: 31210712 DOI: 10.3748/wjg.v25.i21.2591] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
123 Sharma P, Welch K, Hussain H, Pelletier SJ, Fontana RJ, Marrero J, Merion RM. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era. Dig Dis Sci. 2012;57:806-812. [PMID: 21953139 DOI: 10.1007/s10620-011-1910-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
124 Kobayashi K, Maruyama H, Kiyono S, Ogasawara S, Suzuki E, Ooka Y, Chiba T, Kato N, Yamaguchi T. Application of transcutaneous ultrasonography for the diagnosis of muscle mass loss in patients with liver cirrhosis. J Gastroenterol 2018;53:652-9. [DOI: 10.1007/s00535-017-1378-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
125 Lewandowski RJ, Mulcahy MF, Kulik LM, Riaz A, Ryu RK, Baker TB, Ibrahim SM, Abecassis MI, Miller FH, Sato KT, Senthilnathan S, Resnick SA, Wang E, Gupta R, Chen R, Newman SB, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Omary RA, Benson AB 3rd, Salem R. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010;255:955-65. [PMID: 20501733 DOI: 10.1148/radiol.10091473] [Cited by in Crossref: 108] [Cited by in F6Publishing: 95] [Article Influence: 9.8] [Reference Citation Analysis]
126 Badvie S. Hepatocellular carcinoma. Postgrad Med J 2000;76:4-11. [PMID: 10622772 DOI: 10.1136/pmj.76.891.4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 2.6] [Reference Citation Analysis]
127 Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1:e000042. [PMID: 27843598 DOI: 10.1136/esmoopen-2016-000042] [Cited by in Crossref: 108] [Cited by in F6Publishing: 81] [Article Influence: 21.6] [Reference Citation Analysis]
128 Zhang G, Wang Z, Luo W, Jiao H, Wu J, Jiang C. Expression of Potential Cancer Stem Cell Marker ABCG2 is Associated with Malignant Behaviors of Hepatocellular Carcinoma. Gastroenterol Res Pract 2013;2013:782581. [PMID: 24194752 DOI: 10.1155/2013/782581] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
129 Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502-510. [PMID: 19141028 DOI: 10.1111/j.1478-3231.2008.01957.x] [Cited by in Crossref: 199] [Cited by in F6Publishing: 189] [Article Influence: 15.3] [Reference Citation Analysis]
130 Vagefi PA, Dodge JL, Yao FY, Roberts JP. Potential role of the donor in hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2015;21:187-194. [PMID: 25371243 DOI: 10.1002/lt.24042] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
131 Kim PT, Testa G. Living donor liver transplantation in the USA. Hepatobiliary Surg Nutr. 2016;5:133-140. [PMID: 27115007 DOI: 10.3978/j.issn.2304-3881.2015.06.01] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
132 Gruttadauria S, di Francesco F, Gridelli B. Liver transplantation for polycystic liver and massive hepatomegaly. World J Gastroenterol 2010;16:1425-6. [PMID: 20238413 DOI: 10.3748/wjg.v16.i11.1425] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
133 Cheng JW, Shi YH, Fan J, Huang XW, Qiu SJ, Xiao YS, Wang Z, Dai Z, Tang ZY, Zhou J. An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2011;137:1445-1453. [PMID: 21809031 DOI: 10.1007/s00432-011-1014-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
134 Kokudo T, Kokudo N. What liver surgeons have achieved in the recent decade for patients with hepatocellular carcinoma? Glob Health Med 2020;2:265-8. [PMID: 33330819 DOI: 10.35772/ghm.2020.01086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Reference Citation Analysis]
136 Samoylova ML, Dodge JL, Yao FY, Roberts JP. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2014;20:937-44. [PMID: 24797145 DOI: 10.1002/lt.23902] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 8.3] [Reference Citation Analysis]
137 Hibi T, Shinoda M, Itano O, Kitagawa Y. Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine. Organogenesis 2014;10:241-9. [PMID: 24836922 DOI: 10.4161/org.29245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
138 O'Connor DB, Burke JP, Hegarty J, McCormick AP, Nolan N, Hoti E, Maguire D, Geoghegan J, Traynor O. Liver transplantation for hepatocellular carcinoma in Ireland: Pre-operative alpha-fetoprotein predicts tumour recurrence in a 14-year single-centre national experience. World J Transplant. 2016;6:396-402. [PMID: 27358785 DOI: 10.5500/wjt.v6.i2.396] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
139 Facciuto ME, Rochon C, Pandey M, Rodriguez-Davalos M, Samaniego S, Wolf DC, Kim-Schluger L, Rozenblit G, Sheiner PA. Surgical dilemma: liver resection or liver transplantation for hepatocellular carcinoma and cirrhosis. Intention-to-treat analysis in patients within and outwith Milan criteria. HPB (Oxford) 2009;11:398-404. [PMID: 19768144 DOI: 10.1111/j.1477-2574.2009.00073.x] [Reference Citation Analysis]
140 Rude MK, Crippin JS. Liver transplantation for hepatocellular carcinoma. Curr Gastroenterol Rep 2015;17:11. [PMID: 25740250 DOI: 10.1007/s11894-015-0435-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
141 Tran NH, Kisiel J, Roberts LR. Using cell-free DNA for HCC surveillance and prognosis. JHEP Rep 2021;3:100304. [PMID: 34136776 DOI: 10.1016/j.jhepr.2021.100304] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Yamashita YI, Imai K, Kaida T, Yamao T, Tsukamoto M, Nakagawa S, Okabe H, Chikamoto A, Ishiko T, Yoshizumi T, Ikeda T, Maehara Y, Baba H. Multimodal radiofrequency ablation versus laparoscopic hepatic resection for the treatment of primary hepatocellular carcinoma within Milan criteria in severely cirrhotic patients: long-term favorable outcomes over 10 years. Surg Endosc 2019;33:46-51. [PMID: 29872945 DOI: 10.1007/s00464-018-6264-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
143 Ren J, Wu T, Zheng BW, Tan YY, Zheng RQ, Chen GH. Application of contrast-enhanced ultrasound after liver transplantation: Current status and perspectives. World J Gastroenterol 2016;22:1607-16. [PMID: 26819526 DOI: 10.3748/wjg.v22.i4.1607] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
144 Yang Y, Zhou Y, Zhang X, Xin Y, Chen Y, Fan Q, Li X, Wei X, Li Q, Zhou X, Zhou J. Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study. J Hepatocell Carcinoma 2021;8:837-50. [PMID: 34350139 DOI: 10.2147/JHC.S308587] [Reference Citation Analysis]
145 Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Rep 2019;1:17-29. [PMID: 32039350 DOI: 10.1016/j.jhepr.2019.02.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
146 Ibrahim SM, Lewandowski RJ, Sato KT, Gates VL, Kulik L, Mulcahy MF, Ryu RK, Omary RA, Salem R. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 2008;14:1664-9. [PMID: 18350597 DOI: 10.3748/wjg.14.1664] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
147 Charpentier KP, Cheah YL, Machan JT, Miner T, Morrissey P, Monaco A. Intention to treat survival following liver transplantation for hepatocellular carcinoma within a donor service area. HPB (Oxford) 2008;10:412-5. [PMID: 19088926 DOI: 10.1080/13651820802392320] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
148 Cotterell AH, Fisher RA. Ischemia/Reperfusion Injury and Hepatocellular Carcinoma Recurrence After Liver Transplantation: Cancer at WIT's End? Dig Dis Sci 2015;60:2579-80. [PMID: 26031422 DOI: 10.1007/s10620-015-3729-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
149 Yang JF, Lo CH, Huang WY. Is Stereotactic Body Radiotherapy Better Than Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma? J Clin Oncol 2016;34:2797. [PMID: 27325860 DOI: 10.1200/JCO.2016.66.4458] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
150 Xu X, Pu X, Jiang L, Huang Y, Yan L, Yang J, Wen T, Li B, Wu H, Wang W. Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child-Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria. J Cancer Res Clin Oncol 2021;147:607-18. [PMID: 32852635 DOI: 10.1007/s00432-020-03364-x] [Reference Citation Analysis]
151 Seehofer D, Öllinger R, Denecke T, Schmelzle M, Andreou A, Schott E, Pratschke J. Blood Transfusions and Tumor Biopsy May Increase HCC Recurrence Rates after Liver Transplantation. J Transplant 2017;2017:9731095. [PMID: 28154760 DOI: 10.1155/2017/9731095] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
152 Morise Z, Kawabe N, Tomishige H, Nagata H, Kawase J, Arakawa S, Yoshida R, Isetani M. Recent advances in liver resection for hepatocellular carcinoma. Front Surg. 2014;1:21. [PMID: 25593945 DOI: 10.3389/fsurg.2014.00021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
153 Zhang Q, Chen H, Li Q, Zang Y, Chen X, Zou W, Wang L, Shen ZY. Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study. Invest New Drugs 2011;29:1360-9. [PMID: 21809025 DOI: 10.1007/s10637-011-9726-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
154 Harring TR, Guiteau JJ, Nguyen NT, Cotton RT, Gingras MC, Wheeler DA, O'Mahony CA, Gibbs RA, Brunicardi FC, Goss JA. Building a comprehensive genomic program for hepatocellular carcinoma. World J Surg 2011;35:1746-50. [PMID: 21225260 DOI: 10.1007/s00268-010-0954-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
155 Chedid MF, Kruel CRP, Pinto MA, Grezzana-Filho TJM, Leipnitz I, Kruel CDP, Scaffaro LA, Chedid AD. Hepatocellular carcinoma: Diagnosis and operative management. Arq Bras Cir Dig. 2017;30:272-278. [PMID: 29340553 DOI: 10.1590/0102-6720201700040011] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
156 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 132] [Article Influence: 36.5] [Reference Citation Analysis]
157 Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11-e22. [PMID: 22047762 DOI: 10.1016/s1470-2045(11)70175-9.] [Reference Citation Analysis]
158 Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, Sarli D, Schiavo M, Garbagnati F, Marchianò A. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg. 2004;240:900-909. [PMID: 15492574 DOI: 10.1097/01.sla.0000143301.56154.95] [Cited by in Crossref: 356] [Cited by in F6Publishing: 313] [Article Influence: 20.9] [Reference Citation Analysis]
159 Hanna RF, Finkelstone LA, Chow DS, Miloushev VZ, Escudero MR, Lagana SM, Prince MR. Nephrogenic systemic fibrosis risk and liver disease. Int J Nephrol 2014;2014:679605. [PMID: 24778878 DOI: 10.1155/2014/679605] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
160 Grattagliano I, Ubaldi E, Bonfrate L, Portincasa P. Management of liver cirrhosis between primary care and specialists. World J Gastroenterol 2011;17:2273-82. [PMID: 21633593 DOI: 10.3748/wjg.v17.i18.2273] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
161 Ju MR, Yopp AC. Evolving thresholds for liver transplantation in hepatocellular carcinoma: A Western experience. Ann Gastroenterol Surg 2020;4:208-15. [PMID: 32490334 DOI: 10.1002/ags3.12316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
162 Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol 2014;20:4115-27. [PMID: 24764650 DOI: 10.3748/wjg.v20.i15.4115] [Cited by in CrossRef: 231] [Cited by in F6Publishing: 202] [Article Influence: 38.5] [Reference Citation Analysis]
163 Wallace MC, Sek K, Francis RJ, Samuelson S, Ferguson J, Tibballs J, Asad A, Preen DB, MacQuillan G, Garas G, Adams LA, Jeffrey GP. Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy. Dig Dis Sci 2020;65:647-57. [PMID: 31440998 DOI: 10.1007/s10620-019-05781-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
164 Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11:7391-7400. [PMID: 16437707 DOI: 10.3748/wjg.v11.i47.7391] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 91] [Article Influence: 2.4] [Reference Citation Analysis]
165 Mullath A, Krishna M. Hepatocellular carcinoma - time to take the ticket. World J Gastrointest Surg 2019;11:287-95. [PMID: 31367276 DOI: 10.4240/wjgs.v11.i6.287] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
166 Zhang Q, Chen X, Zang Y, Zhang L, Chen H, Wang L, Niu Y, Ren X, Shen Z, Shang L. The survival benefit of liver transplantation for hepatocellular carcinoma patients with hepatitis B virus infection and cirrhosis. PLoS One. 2012;7:e50919. [PMID: 23236406 DOI: 10.1371/journal.pone.0050919] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
167 Xing M, Kim HS. Independent prognostic factors for posttransplant survival in hepatocellular carcinoma patients undergoing liver transplantation. Cancer Med 2017;6:26-35. [PMID: 27860456 DOI: 10.1002/cam4.936] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
168 Citores MJ, Lucena JL, de la Fuente S, Cuervas-Mons V. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation. World J Hepatol 2019;11:50-64. [PMID: 30705718 DOI: 10.4254/wjh.v11.i1.50] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
169 Rauchfuß F, Dondorf F, Fahrner R, Tautenhahn HM, Ardelt M, Settmacher U. Searching the ideal hepatocellular carcinoma patient for liver transplantation: are the Toronto criteria a step in the right direction? Hepatobiliary Surg Nutr 2017;6:342-3. [PMID: 29152484 DOI: 10.21037/hbsn.2017.05.14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
170 Burgmans MC, Too CW, Fiocco M, Kerbert AJ, Lo RH, Schaapman JJ, van Erkel AR, Coenraad MJ, Tan BS. Differences in Patient Characteristics and Midterm Outcome Between Asian and European Patients Treated with Radiofrequency Ablation for Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2016;39:1708-15. [PMID: 27671151 DOI: 10.1007/s00270-016-1462-7] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
171 Viveiros A, Zoller H, Finkenstedt A. Hepatocellular carcinoma: when is liver transplantation oncologically futile? Transl Gastroenterol Hepatol 2017;2:63. [PMID: 28815223 DOI: 10.21037/tgh.2017.07.03] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
172 Eltawil KM, Berry R, Abdolell M, Molinari M. Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre. HPB (Oxford) 2012;14:162-70. [PMID: 22321034 DOI: 10.1111/j.1477-2574.2011.00420.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
173 Vasuri F, Golfieri R, Fiorentino M, Capizzi E, Renzulli M, Pinna AD, Grigioni WF, D’errico-grigioni A. OATP 1B1/1B3 expression in hepatocellular carcinomas treated with orthotopic liver transplantation. Virchows Arch 2011;459:141-6. [DOI: 10.1007/s00428-011-1099-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
174 Miwa T, Hatano Y, Kochi T, Aiba M, Toda K, Goto H, Nakamura N, Katsumura N, Imai K, Shimizu M. Spur cell anemia related to alcoholic liver cirrhosis managed without liver transplantation: a case report and literature review. Clin J Gastroenterol 2020;13:882-90. [PMID: 32472376 DOI: 10.1007/s12328-020-01142-3] [Reference Citation Analysis]
175 Tarantino G, Magistri P, Ballarin R, Di Francia R, Berretta M, Di Benedetto F. Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature. Front Pharmacol 2016;7:387. [PMID: 27818634 DOI: 10.3389/fphar.2016.00387] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
176 Wang H, Feng LH, Qian YW, Cao ZY, Wu MC, Cong WM. Does microvascular invasion in Barcelona Clinic Liver Cancer stage A multinodular hepatocellular carcinoma indicate early-stage behavior? Ann Transl Med 2019;7:428. [PMID: 31700864 DOI: 10.21037/atm.2019.08.114] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
177 Waller LP, Deshpande V, Pyrsopoulos N. Hepatocellular carcinoma: A comprehensive review. World J Hepatol. 2015;7:2648-2663. [PMID: 26609342 DOI: 10.4254/wjh.v7.i26.2648] [Cited by in Crossref: 115] [Cited by in F6Publishing: 104] [Article Influence: 19.2] [Reference Citation Analysis]
178 Duvoux C, Kiuchi T, Pestalozzi B, Busuttil R, Miksad R. What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma? Liver Transpl 2011;17 Suppl 2:S147-58. [PMID: 21714065 DOI: 10.1002/lt.22367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
179 Lorente L, Rodriguez ST, Sanz P, Pérez-Cejas A, Padilla J, Díaz D, González A, Martín MM, Jiménez A, Cerro P, Barrera MA. Patients with high serum substance P levels previously to liver transplantation for hepatocellular carcinoma have higher risk of one-year liver transplantation mortality. Oncotarget 2018;9:21552-9. [PMID: 29765559 DOI: 10.18632/oncotarget.25097] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
180 Gu XQ, Zheng WP, Teng DH, Sun JS, Zheng H. Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients. World J Gastroenterol 2016;22:2749-59. [PMID: 26973413 DOI: 10.3748/wjg.v22.i9.2749] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
181 Zhang J, Ren FG, Liu P, Zhang HK, Zhu HY, Feng Z, Zhang XF, Wang B, Liu XM, Zhang XG, Wu RQ, Lv Y. Characteristics of fecal microbial communities in patients with non-anastomotic biliary strictures after liver transplantation. World J Gastroenterol 2017;23:8217-26. [PMID: 29290658 DOI: 10.3748/wjg.v23.i46.8217] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
182 Johnson PJ. Non-surgical treatment of hepatocellular carcinoma. HPB (Oxford). 2005;7:50-55. [PMID: 18333161 DOI: 10.1080/13651820410024076] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
183 Ji W, Chen J, Mi Y, Wang G, Xu X, Wang W. Role of natural killer cells in liver transplantation treatment of liver cancer. Exp Ther Med 2017;14:2380-4. [PMID: 28962171 DOI: 10.3892/etm.2017.4748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
184 Zhong JH, Torzilli G, Xing H, Li C, Han J, Liang L, Zhang H, Dai SY, Li LQ, Shen F, Yang T. Controversies and evidence of hepatic resection for hepatocellular carcinoma. BBA Clin. 2016;6:125-130. [PMID: 27761414 DOI: 10.1016/j.bbacli.2016.10.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
185 Abdel-Rahman O, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2020;1:CD011313. [PMID: 31978267 DOI: 10.1002/14651858.CD011313.pub3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
186 Hibi T, Itano O, Shinoda M, Kitagawa Y. Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun. Surg Today 2017;47:403-15. [PMID: 27130463 DOI: 10.1007/s00595-016-1337-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
187 Maiwald B, Lobsien D, Kahn T, Stumpp P. Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma? PLoS One. 2014;9:e111935. [PMID: 25375778 DOI: 10.1371/journal.pone.0111935] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
188 Lerut J, Iesari S, Foguenne M, Lai Q. Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression? Transl Gastroenterol Hepatol 2017;2:80. [PMID: 29167827 DOI: 10.21037/tgh.2017.09.06] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
189 Vasuri F, Malvi D, Rosini F, Baldin P, Fiorentino M, Paccapelo A, Ercolani G, Pinna AD, Golfieri R, Morselli-Labate AM, Grigioni WF, D'Errico-Grigioni A. Revisiting the role of pathological analysis in transarterial chemoembolization-treated hepatocellular carcinoma after transplantation. World J Gastroenterol 2014;20:13538-45. [PMID: 25309084 DOI: 10.3748/wjg.v20.i37.13538] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
190 Truong BX, Yano Y, VAN VT, Seo Y, Nam NH, Trach NK, Utsumi T, Azuma T, Hayashi Y. Clinical utility of protein induced by vitamin K absence in patients with chronic hepatitis B virus infection. Biomed Rep. 2013;1:122-128. [PMID: 24648907 DOI: 10.3892/br.2012.4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
191 Hiraoka A, Kumada T, Kudo M, Hirooka M, Tsuji K, Itobayashi E, Kariyama K, Ishikawa T, Tajiri K, Ochi H, Tada T, Toyoda H, Nouso K, Joko K, Kawasaki H, Hiasa Y, Michitaka K; Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics). Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. Liver Cancer. 2017;6:204-215. [PMID: 28626732 DOI: 10.1159/000452846] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 15.5] [Reference Citation Analysis]
192 Siegel AB, El-Khoueiry AB, Finn RS, Guthrie KA, Goyal A, Venook AP, Blanke CD, Verna EC, Dove L, Emond J, Kato T, Samstein B, Busuttil R, Remotti H, Coffey A, Brown RS Jr. Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma. Liver Cancer 2015;4:115-25. [PMID: 26020033 DOI: 10.1159/000367734] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
193 Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer 2013;4:635-43. [PMID: 24155775 DOI: 10.7150/jca.7279] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
194 Senkerikova R, Frankova S, Jirsa M, Kreidlova M, Merta D, Neroldova M, Chmelova K, Spicak J, Sperl J. PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age. PLoS One 2019;14:e0222609. [PMID: 31527889 DOI: 10.1371/journal.pone.0222609] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
195 Tokumitsu Y, Sakamoto K, Tokuhisa Y, Matsui H, Matsukuma S, Maeda Y, Sakata K, Wada H, Eguchi H, Ogihara H, Fujita Y, Hamamoto Y, Iizuka N, Ueno T, Nagano H. A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy. Oncol Lett 2018;15:4411-22. [PMID: 29556288 DOI: 10.3892/ol.2018.7821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
196 Weis S, Franke A, Berg T, Mössner J, Fleig WE, Schoppmeyer K. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev 2015;1:CD006745. [PMID: 25620061 DOI: 10.1002/14651858.CD006745.pub3] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
197 Asmis T, Balaa F, Scully L, Papadatos D, Marginean C, Fasih N, Shaw-Stiffel T, Goel R. Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre. Curr Oncol 2010;17:6-12. [PMID: 20404972 DOI: 10.3747/co.v17i2.555] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
198 Wang L, Wang J, Zhang X, Li J, Wei X, Cheng J, Ling Q, Xie H, Zhou L, Xu X, Zheng S. Diagnostic Value of Preoperative Needle Biopsy for Tumor Grading Assessment in Hepatocellular Carcinoma. PLoS One. 2015;10:e0144216. [PMID: 26658912 DOI: 10.1371/journal.pone.0144216] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
199 Truty MJ, Vauthey JN. Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations, and operative technique. Ann Surg Oncol. 2010;17:1219-1225. [PMID: 20405326 DOI: 10.1245/s10434-010-0976-5] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 5.4] [Reference Citation Analysis]
200 Ming M, Ying M, Ling M. miRNA-125a-5p inhibits hepatocellular carcinoma cell proliferation and induces apoptosis by targeting TP53 regulated inhibitor of apoptosis 1 and Bcl-2-like-2 protein. Exp Ther Med 2019;18:1196-202. [PMID: 31316614 DOI: 10.3892/etm.2019.7674] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
201 Lupo L, Panzera P, Giannelli G, Memeo M, Gentile A, Memeo V. Single hepatocellular carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection? HPB (Oxford). 2007;9:429-434. [PMID: 18345289 DOI: 10.1080/13651820701713758] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 5.5] [Reference Citation Analysis]
202 Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol. 2010;17:1226-1233. [PMID: 20405327 DOI: 10.1245/s10434-010-0978-3] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 5.1] [Reference Citation Analysis]
203 Xiong MJ, Patel CR, Manne U, Al Diffalha S. Cirrhotomimetic hepatocellular carcinoma: experience of a single institution and review of the literature. Hepat Oncol 2020;8:HEP28. [PMID: 33680429 DOI: 10.2217/hep-2020-0015] [Reference Citation Analysis]
204 Chu KK, Chan SC, Sharr WW, Chok KS, Dai WC, Lo CM. Low-volume deceased donor liver transplantation alongside a strong living donor liver transplantation service. World J Surg 2014;38:1522-8. [PMID: 24385193 DOI: 10.1007/s00268-013-2437-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
205 Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, Denninger MH, Sauvanet A, Valla D, Durand F. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005;54:691-7. [PMID: 15831918 DOI: 10.1136/gut.2004.042796] [Cited by in Crossref: 351] [Cited by in F6Publishing: 281] [Article Influence: 21.9] [Reference Citation Analysis]
206 Ruzzenente A, Bagante F, Bertuzzo F, Aldrighetti L, Campagnaro T, Ercolani G, Conci S, Giuliante F, Dore A, Ferrero A, Torzilli G, Grazi GL, Ratti F, Cucchetti A, De Rose AM, Russolillo N, Cimino M, Perri P, Guglielmi A, Iacono C. Liver Resection for Neuroendocrine Tumor Liver Metastases Within Milan Criteria for Liver Transplantation. J Gastrointest Surg 2019;23:93-100. [PMID: 30242647 DOI: 10.1007/s11605-018-3973-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
207 Kim SH, Lee EC, Park SJ. Pretransplant locoregional therapy for hepatocellular carcinoma: encouraging but insufficient. Hepatobiliary Surg Nutr. 2018;7:136-137. [PMID: 29744345 DOI: 10.21037/hbsn.2018.01.08] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
208 Liu S, Li H, Guo L, Zhang B, Zhou B, Zhang W, Zhou J, Fan J, Ye Q. Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion. Oncologist. 2019;24:513-520. [PMID: 30552155 DOI: 10.1634/theoncologist.2018-0305] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
209 Gunay Y, Guler N, Yaprak O, Dayangac M, Akyildiz M, Altaca G, Yuzer Y, Tokat Y. Living Donor Liver Transplantation Outcomes for Hepatocellular Carcinoma Beyond Milan or UCSF Criteria. Indian J Surg 2015;77:950-6. [PMID: 27011489 DOI: 10.1007/s12262-014-1078-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
210 Tsai DF, Huang SW, Holm S, Lin YP, Chang YK, Hsu CC. The outcomes and controversies of transplant tourism-Lessons of an 11-year retrospective cohort study from Taiwan. PLoS One. 2017;12:e0178569. [PMID: 28575014 DOI: 10.1371/journal.pone.0178569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
211 Jung J, Yoon SM, Kim SY, Cho B, Park JH, Kim SS, Song SY, Lee SW, Ahn SD, Choi EK. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters. Radiat Oncol. 2013;8:249. [PMID: 24160910 DOI: 10.1186/1748-717x-8-249] [Cited by in Crossref: 72] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
212 Llovet JM, Paradis V, Kudo M, Zucman-Rossi J. Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transpl. 2011;17 Suppl 2:S67-S71. [PMID: 21594967 DOI: 10.1002/lt.22340] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
213 Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, Sato KT, Marshall K, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Senthilnathan S, Baker T, Gates VL, Abecassis M, Benson AB 3rd, Mulcahy MF, Omary RA, Salem R. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011;141:526-35, 535.e1-2. [PMID: 21664356 DOI: 10.1053/j.gastro.2011.04.054] [Cited by in Crossref: 117] [Cited by in F6Publishing: 101] [Article Influence: 11.7] [Reference Citation Analysis]
214 Ho CM, Lee PH, Cheng WT, Hu RH, Wu YM, Ho MC. Succinct guide to liver transplantation for medical students. Ann Med Surg (Lond) 2016;12:47-53. [PMID: 27895907 DOI: 10.1016/j.amsu.2016.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
215 Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, Bolondi L, Negrini M. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 2008;12:2189-204. [PMID: 19120703 DOI: 10.1111/j.1582-4934.2008.00533.x] [Cited by in Crossref: 182] [Cited by in F6Publishing: 176] [Article Influence: 15.2] [Reference Citation Analysis]
216 Weledji EP, Enow Orock G, Ngowe MN, Nsagha DS. How grim is hepatocellular carcinoma? Ann Med Surg (Lond) 2014;3:71-6. [PMID: 25568791 DOI: 10.1016/j.amsu.2014.06.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
217 She WH, Cheung TT. Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation. Transl Gastroenterol Hepatol. 2016;1:34. [PMID: 28138601 DOI: 10.21037/tgh.2016.03.04] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
218 Solbach P, Potthoff A, Raatschen HJ, Soudah B, Lehmann U, Schneider A, Gebel MJ, Manns MP, Vogel A. Testosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: a case report. BMC Gastroenterol 2015;15:60. [PMID: 25986067 DOI: 10.1186/s12876-015-0288-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
219 Braunwarth E, Stättner S, Fodor M, Cardini B, Resch T, Oberhuber R, Putzer D, Bale R, Maglione M, Margreiter C, Schneeberger S, Öfner D, Primavesi F. Surgical techniques and strategies for the treatment of primary liver tumours: hepatocellular and cholangiocellular carcinoma. Eur Surg 2018;50:100-12. [PMID: 29875798 DOI: 10.1007/s10353-018-0537-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
220 Kornberg A, Schernhammer M, Friess H. 18F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma. J Clin Transl Hepatol 2017;5:224-34. [PMID: 28936404 DOI: 10.14218/JCTH.2017.00014] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
221 Lorente L, Rodriguez ST, Sanz P, Pérez-Cejas A, Abreu-González P, Padilla J, Díaz D, González A, Martín MM, Jiménez A, Cerro P, Barrera MA. Serum total antioxidant capacity prior to liver transplantation for hepatocellular carcinoma is associated with 1-year liver transplantation survival. J Int Med Res 2018;46:2641-9. [PMID: 29911482 DOI: 10.1177/0300060518768150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
222 Samuel D, Coilly A. Management of patients with liver diseases on the waiting list for transplantation: a major impact to the success of liver transplantation. BMC Med 2018;16:113. [PMID: 30064414 DOI: 10.1186/s12916-018-1110-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
223 Mathur A, Franco ES, Leone JP, Osman-Mohamed H, Rojas H, Kemmer N, Neff GW, Rosemurgy AS, Alsina AE. Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma. HPB (Oxford). 2013;15:504-510. [PMID: 23750492 DOI: 10.1111/j.1477-2574.2012.00602.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
224 Jun CH, Ki HS, Lee KH, Park KJ, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK. Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE. Clin Mol Hepatol. 2013;19:70-77. [PMID: 23593612 DOI: 10.3350/cmh.2013.19.1.70] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
225 Collettini F, Schnapauff D, Poellinger A, Denecke T, Schott E, Berg T, Wust P, Hamm B, Gebauer B. Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5-7 cm) and very large (>7 cm) tumours. Eur Radiol 2012;22:1101-9. [PMID: 22173693 DOI: 10.1007/s00330-011-2352-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
226 Shiina S. Image-guided percutaneous ablation therapies for hepatocellular carcinoma. J Gastroenterol 2009;44:122-31. [DOI: 10.1007/s00535-008-2263-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
227 Mancuso A, Perricone G. Hepatocellular Carcinoma and Liver Transplantation: State of the Art. J Clin Transl Hepatol 2014;2:176-81. [PMID: 26357625 DOI: 10.14218/JCTH.2014.00013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
228 Trojan J, Zangos S, Schnitzbauer AA. Diagnostics and Treatment of Hepatocellular Carcinoma in 2016: Standards and Developments. Visc Med. 2016;32:116-120. [PMID: 27413729 DOI: 10.1159/000445730] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
229 Yip D, Findlay M, Boyer M, Tattersall MH. Hepatocellular carcinoma in central Sydney:a 10-year review of patients seen in a medical oncology department. World J Gastroenterol 1999;5:483-7. [PMID: 11819496 DOI: 10.3748/wjg.v5.i6.483] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
230 Orlacchio A, Chegai F, Merolla S, Francioso S, Giudice CD, Angelico M, Tisone G, Simonetti G. Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization. World J Hepatol. 2015;7:1694-1700. [PMID: 26140089 DOI: 10.4254/wjh.v7.i12.1694] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
231 Fahrner R, Dondorf F, Ardelt M, Dittmar Y, Settmacher U, Rauchfuß F. Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival. World J Gastroenterol 2015;21:12071-82. [PMID: 26576092 DOI: 10.3748/wjg.v21.i42.12071] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
232 Lee SD, Lee B, Kim SH, Joo J, Kim SK, Kim YK, Park SJ. Proposal of new expanded selection criteria using total tumor size and (18)F-fluorodeoxyglucose - positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National Cancer Center Korea criteria. World J Transplant. 2016;6:411-422. [PMID: 27358787 DOI: 10.5500/wjt.v6.i2.411] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
233 Knechtle SJ, Kalayoglu M, D'Alessandro AM, Rikkers LF. Proceed with caution: liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997;225:345-6. [PMID: 9114791 DOI: 10.1097/00000658-199704000-00001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
234 Chen HY, Han ZB, Fan JW, Xia J, Wu JY, Qiu GQ, Tang HM, Peng ZH. miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver. Med Oncol. 2012;29:1859-1865. [PMID: 21786180 DOI: 10.1007/s12032-011-0031-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
235 Allen J, Venook A. Hepatocellular carcinoma: epidemic and treatment. Curr Oncol Rep 2004;6:177-83. [PMID: 15066228 DOI: 10.1007/s11912-004-0047-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
236 Lee WC, Wang YC, Cheng CH, Wu TH, Lee CF, Wu TJ, Chou HS, Chan KM. Myeloid-derived suppressor cells in the patients with liver resection for hepatitis B virus-related hepatocellular carcinoma. Sci Rep 2019;9:2269. [PMID: 30783140 DOI: 10.1038/s41598-019-38785-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
237 Wu X, Zhang X, Tao L, Dai X, Chen P. Prognostic Value of an m6A RNA Methylation Regulator-Based Signature in Patients with Hepatocellular Carcinoma. Biomed Res Int 2020;2020:2053902. [PMID: 32733931 DOI: 10.1155/2020/2053902] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
238 Bzowej N, Han S, Degertekin B, Keeffe EB, Emre S, Brown R, Reddy R, Lok AS; National Institutes of Health Hepatitis B Virus Orthotopic Liver Transplantation Study Group. Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. Liver Transpl 2009;15:1010-20. [PMID: 19718627 DOI: 10.1002/lt.21759] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
239 Hennedige T, Anil G, Madhavan K. Expectations from imaging for pre-transplant evaluation of living donor liver transplantation. World J Radiol 2014;6:693-707. [PMID: 25276312 DOI: 10.4329/wjr.v6.i9.693] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
240 Hu Z, Li Z, Xiang J, Zhou J, Yan S, Wu J, Zhou L, Zheng S. Intent-to-treat analysis of liver transplant for hepatocellular carcinoma in the MELD era: impact of hepatitis C and advanced status. Dig Dis Sci 2014;59:3062-72. [PMID: 25008426 DOI: 10.1007/s10620-014-3266-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
241 Li C, Zhang F, Zhang W, Zhang L, Huang Z, Wu P. Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136:1633-1640. [PMID: 20865361 DOI: 10.1007/s00432-010-0821-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
242 Cho Y, Kim MS, Nam CM, Kang ES. Statin Use is Associated with Decreased Hepatocellular Carcinoma Recurrence in Liver Transplant Patients. Sci Rep 2019;9:1467. [PMID: 30728421 DOI: 10.1038/s41598-018-38110-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
243 Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Aramaki T, Uesaka K. The tumor diameter cut-off for predicting microscopic intrahepatic metastasis of hepatocellular carcinoma patients without treatment history differs from that of hepatocellular carcinoma patients with a treatment history. Clin Transl Oncol 2020;22:319-29. [PMID: 31041718 DOI: 10.1007/s12094-019-02120-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
244 Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, Durand F, Bernard PH, Boillot O, Compagnon P, Calmus Y, Hardwigsen J, Ducerf C, Pageaux GP, Dharancy S, Chazouillères O, Cherqui D, Duvoux C. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol 2006;12:7319-25. [PMID: 17143948 DOI: 10.3748/wjg.v12.i45.7319] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
245 Sastre J, Díaz-Beveridge R, García-Foncillas J, Guardeño R, López C, Pazo R, Rodriguez-Salas N, Salgado M, Salud A, Feliu J. Clinical guideline SEOM: hepatocellular carcinoma. Clin Transl Oncol 2015;17:988-95. [PMID: 26607931 DOI: 10.1007/s12094-015-1451-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
246 Schwartz M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein S, Marsh JW, Martignetti JA, Llovet JM. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol. 2008;49:581-588. [PMID: 18602719 DOI: 10.1016/j.jhep.2008.03.032] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 4.8] [Reference Citation Analysis]
247 Wei Z, Doria C, Liu Y. Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol 2013;7:87-102. [PMID: 23761989 DOI: 10.4137/CMO.S7633] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
248 Riaz A, Lewandowski RJ, Kulik L, Ryu RK, Mulcahy MF, Baker T, Gates V, Nayar R, Wang E, Miller FH. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol. 2010;33:1143-1152. [PMID: 19967371 DOI: 10.1007/s00270-009-9766-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 6.4] [Reference Citation Analysis]
249 Levi Sandri GB, Lai Q. Twenty years after: from Milan criteria to a "blended" approach. Transl Gastroenterol Hepatol 2017;2:62. [PMID: 28815222 DOI: 10.21037/tgh.2017.07.01] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
250 Nathan H, Hyder O, Mayo SC, Hirose K, Wolfgang CL, Choti MA, Pawlik TM. Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis. Ann Surg. 2013;258:1022-1027. [PMID: 23299519 DOI: 10.1097/sla.0b013e31827da749] [Cited by in Crossref: 42] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
251 Hasegawa K, Kokudo N. Surgical treatment of hepatocellular carcinoma. Surg Today 2009;39:833-43. [PMID: 19784720 DOI: 10.1007/s00595-008-4024-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
252 Ito K, Takemura N, Inagaki F, Mihara F, Kokudo N. Difference in treatment algorithms for hepatocellular carcinoma between world's principal guidelines. Glob Health Med. 2020;2:282-291. [PMID: 33330822 DOI: 10.35772/ghm.2020.01066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
253 Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 294] [Article Influence: 31.0] [Reference Citation Analysis]
254 Chen B, Garmire L, Calvisi DF, Chua MS, Kelley RK, Chen X. Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2020;17:238-51. [PMID: 31900465 DOI: 10.1038/s41575-019-0240-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 29.0] [Reference Citation Analysis]
255 Nissen NN, Barin B, Stock PG. Malignancy in the HIV-infected patients undergoing liver and kidney transplantation. Curr Opin Oncol. 2012;24:517-521. [PMID: 22759736 DOI: 10.1097/cco.0b013e328355e0d7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
256 Varma V, Mehta N, Kumaran V, Nundy S. Indications and contraindications for liver transplantation. Int J Hepatol. 2011;2011:121862. [PMID: 22007310 DOI: 10.4061/2011/121862] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
257 Nalesnik MA, Tseng G, Ding Y, Xiang GS, Zheng ZL, Yu Y, Marsh JW, Michalopoulos GK, Luo JH. Gene deletions and amplifications in human hepatocellular carcinomas: correlation with hepatocyte growth regulation. Am J Pathol 2012;180:1495-508. [PMID: 22326833 DOI: 10.1016/j.ajpath.2011.12.021] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.2] [Reference Citation Analysis]
258 Yacoub JH, Hsu CC, Fishbein TM, Mauro D, Moon A, He AR, Bashir MR, Burke LMB. Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation-part one: curative intention. Abdom Radiol (NY) 2021;46:3528-39. [PMID: 33835223 DOI: 10.1007/s00261-021-03069-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
259 Kondo Y, Kimura O, Shimosegawa T. Significant biomarkers for the management of hepatocellular carcinoma. Clin J Gastroenterol 2015;8:109-15. [PMID: 25855582 DOI: 10.1007/s12328-015-0568-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
260 Varma V, Webb K, Mirza DF. Liver transplantation for alcoholic liver disease. World J Gastroenterol 2010;16:4377-93. [PMID: 20845504 DOI: 10.3748/wjg.v16.i35.4377] [Reference Citation Analysis]
261 Yamamoto J, Iwatsuki S, Kosuge T, Dvorchik I, Shimada K, Marsh JW, Yamasaki S, Starzl TE. Should hepatomas be treated with hepatic resection or transplantation? Cancer. 1999;86:1151-1158. [PMID: 10506698 DOI: 10.1002/(sici)1097-0142(19991001)86] [Reference Citation Analysis]
262 Baek MY, Yoo JJ, Jeong SW, Jang JY, Kim YK, Jeong SO, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim YJ, Park SY. Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization. Korean J Intern Med 2019;34:1223-32. [PMID: 30360019 DOI: 10.3904/kjim.2018.058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
263 Chen J. The prognostic analysis of different metastatic patterns in advanced liver cancer patients: A population based analysis. PLoS One 2018;13:e0200909. [PMID: 30102707 DOI: 10.1371/journal.pone.0200909] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
264 Zulehner G, Mikula M, Schneller D, van Zijl F, Huber H, Sieghart W, Grasl-Kraupp B, Waldhör T, Peck-Radosavljevic M, Beug H. Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence. Am J Pathol. 2010;176:472-481. [PMID: 20008139 DOI: 10.2353/ajpath.2010.090300] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 5.4] [Reference Citation Analysis]
265 Ren QQ, Fu SJ, Zhao Q, Guo ZY, Ji F, Chen MG, Wu LW, He XS. Prognostic value of preoperative peripheral monocyte count in patients with hepatocellular carcinoma after liver transplantation. Tumour Biol 2016;37:8973-8. [PMID: 26753965 DOI: 10.1007/s13277-015-4758-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
266 She WH, Chok KSh. Strategies to increase the resectability of hepatocellular carcinoma. World J Hepatol. 2015;7:2147-2154. [PMID: 26328026 DOI: 10.4254/wjh.v7.i18.2147] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
267 Likhitsup A, Parikh ND. Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. Pharmacoeconomics 2020;38:5-24. [PMID: 31573053 DOI: 10.1007/s40273-019-00839-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
268 Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A;  OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11-e22. [PMID: 22047762 DOI: 10.1016/s1470-2045(11)70175-9] [Cited by in Crossref: 600] [Cited by in F6Publishing: 221] [Article Influence: 60.0] [Reference Citation Analysis]
269 Sohal DP, Sun W. Hepatocellular carcinoma: prevention and therapy. Curr Oncol Rep. 2011;13:186-194. [PMID: 21409527 DOI: 10.1007/s11912-011-0165-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
270 Galuppo R, McCall A, Gedaly R. The role of bridging therapy in hepatocellular carcinoma. Int J Hepatol. 2013;2013:419302. [PMID: 24455285 DOI: 10.1155/2013/419302] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
271 Chang Y, Gallon L, Shetty K, Chang Y, Jay C, Levitsky J, Ho B, Baker T, Ladner D, Friedewald J. Simulation modeling of the impact of proposed new simultaneous liver and kidney transplantation policies. Transplantation. 2015;99:424-430. [PMID: 25099700 DOI: 10.1097/tp.0000000000000270] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
272 Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M. Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer. 2017;6:325-336. [PMID: 29234636 DOI: 10.1159/000479984] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 16.0] [Reference Citation Analysis]
273 Andres A, Oldani G, Berney T, Compagnon P, Line PD, Toso C. Transplantation for colorectal metastases: on the edge of a revolution. Transl Gastroenterol Hepatol. 2018;3:74. [PMID: 30363763 DOI: 10.21037/tgh.2018.08.04] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
274 Lee SY, Ahn CS, Yoon YI, Lee SG, Hwang S, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Park GC. Long-term outcomes of liver resection for multiple hepatocellular carcinomas: Single-institution experience with 187 patients. Ann Hepatobiliary Pancreat Surg. 2020;24:437-444. [PMID: 33234746 DOI: 10.14701/ahbps.2020.24.4.437] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
275 Shukla A, Vadeyar H, Rela M, Shah S. Liver Transplantation: East versus West. J Clin Exp Hepatol 2013;3:243-53. [PMID: 25755506 DOI: 10.1016/j.jceh.2013.08.004] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
276 Turner PM, Turner TJ. Validation of the crisis triage rating scale for psychiatric emergencies. Can J Psychiatry. 1991;36:651-654. [PMID: 1773400 DOI: 10.1136/gut.51.4.459] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 2.6] [Reference Citation Analysis]
277 Tsoulfas G, Agorastou P, Tooulias A, Marakis GN. Current and future challenges in the surgical treatment of hepatocellular carcinoma: a review. Int Surg 2014;99:779-86. [PMID: 25437587 DOI: 10.9738/INTSURG-D-13-00122.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
278 Xu X, Guo HJ, Xie HY, Li J, Zhuang RZ, Ling Q, Zhou L, Wei XY, Liu ZK, Ding SM, Chen KJ, Xu ZY, Zheng SS. ZIP4, a novel determinant of tumor invasion in hepatocellular carcinoma, contributes to tumor recurrence after liver transplantation. Int J Biol Sci. 2014;10:245-256. [PMID: 24643086 DOI: 10.7150/ijbs.7401] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
279 Beaton MD, Adams PC. Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis. Can J Gastroenterol 2006;20:257-60. [PMID: 16609753 DOI: 10.1155/2006/428048] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
280 Benhammou JN, Aby ES, Shirvanian G, Manansala K, Hussain SK, Tong MJ. Improved survival after treatments of patients with nonalcoholic fatty liver disease associated hepatocellular carcinoma. Sci Rep 2020;10:9902. [PMID: 32555268 DOI: 10.1038/s41598-020-66507-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
281 Kwak BJ, Kim DG, Han JH, Choi HJ, Bae SH, You YK, Choi JY, Yoon SK. Clinical outcome of 1,000 consecutive cases of liver transplantation: a single center experience. Ann Surg Treat Res 2018;95:267-77. [PMID: 30402445 DOI: 10.4174/astr.2018.95.5.267] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
282 Foerster F, Hoppe-Lotichius M, Vollmar J, Marquardt JU, Weinmann A, Wörns MA, Otto G, Zimmermann T, Galle PR. Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre. United European Gastroenterol J 2019;7:838-49. [PMID: 31316788 DOI: 10.1177/2050640619840221] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
283 Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844-855. [PMID: 24531850 DOI: 10.1136/gutjnl-2013-306627] [Cited by in Crossref: 790] [Cited by in F6Publishing: 754] [Article Influence: 112.9] [Reference Citation Analysis]
284 Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J, Perrin H, Azoulay D. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg. 1997;226:688-701; discussion 701-703. [PMID: 9409568 DOI: 10.1097/00000658-199712000-00006] [Cited by in Crossref: 374] [Cited by in F6Publishing: 340] [Article Influence: 16.3] [Reference Citation Analysis]
285 Qian X, Liu S, Long H, Zhang S, Yan X, Yao M, Zhou J, Gong J, Wang J, Wen X, Zhou T, Zhai X, Xu Q, Zhang T, Chen X, Hu G, Wang J, Gao Z, Nan Y, Chen J, Hu B, Zhao J, Lu F. Reappraisal of the diagnostic value of alpha-fetoprotein for surveillance of HBV-related hepatocellular carcinoma in the era of antiviral therapy. J Viral Hepat 2021;28:20-9. [PMID: 32852885 DOI: 10.1111/jvh.13388] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
286 Bremner KE, Bayoumi AM, Sherman M, Krahn MD. Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis. Can J Gastroenterol 2007;21:491-500. [PMID: 17703248 DOI: 10.1155/2007/182383] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
287 Ruff SM, Rothermel LD, Diggs LP, Wach MM, Ayabe RI, Martin SP, Boulware D, Anaya D, Davis JL, Mullinax JE, Hernandez JM. Tumor grade may be used to select patients with multifocal hepatocellular carcinoma for resection. HPB (Oxford) 2020;22:1004-10. [PMID: 31734237 DOI: 10.1016/j.hpb.2019.10.1531] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
288 Bucalau AM, Tancredi I, Pezzullo M, Leveque R, Picchia S, Laethem JV, Verset G. Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes. Hepat Oncol 2020;8:HEP31. [PMID: 33680430 DOI: 10.2217/hep-2020-0022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
289 Obed A, Tsui TY, Schnitzbauer AA, Obed M, Schlitt HJ, Becker H, Lorf T. Liver transplantation as curative approach for advanced hepatocellular carcinoma: is it justified? Langenbecks Arch Surg 2008;393:141-7. [PMID: 18043937 DOI: 10.1007/s00423-007-0250-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
290 Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, Huo TI, Lee SD. Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. Hepatol Int 2013;7:645-54. [PMID: 26201797 DOI: 10.1007/s12072-012-9375-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
291 de'Angelis N, Landi F, Carra MC, Azoulay D. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. World J Gastroenterol. 2015;21:11185-11198. [PMID: 26494973 DOI: 10.3748/wjg.v21.i39.11185] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 48] [Article Influence: 13.2] [Reference Citation Analysis]
292 Chua TC, Saxena A, Chu F, Liauw W, Zhao J, Morris DL. Clinicopathological determinants of survival after hepatic resection of hepatocellular carcinoma in 97 patients--experience from an Australian hepatobiliary unit. J Gastrointest Surg 2010;14:1370-80. [PMID: 20585991 DOI: 10.1007/s11605-010-1277-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
293 Tsim NC, Frampton AE, Habib NA, Jiao LR. Surgical treatment for liver cancer. World J Gastroenterol. 2010;16:927-933. [PMID: 20180230 DOI: 10.3748/wjg.v16.i8.927] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
294 Squires MH, Hanish SI, Fisher SB, Garrett C, Kooby DA, Sarmiento JM, Cardona K, Adams AB, Russell MC, Magliocca JF. Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times. J Surg Oncol. 2014;109:533-541. [PMID: 24347475 DOI: 10.1002/jso.23531] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
295 Chan SC, Fan ST. Historical perspective of living donor liver transplantation. World J Gastroenterol 2008;14:15-21. [PMID: 18176956 DOI: 10.3748/wjg.14.15] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
296 Müller C. Hepatocellular carcinoma – Rising incidence, changing therapeutic strategies. Wien Med Wochenschr 2006;156:404-9. [DOI: 10.1007/s10354-006-0316-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
297 Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology 2013;58:2188-97. [PMID: 23512791 DOI: 10.1002/hep.26382] [Cited by in Crossref: 109] [Cited by in F6Publishing: 98] [Article Influence: 13.6] [Reference Citation Analysis]
298 Canavan C, Eisenburg J, Meng L, Corey K, Hur C. Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK. Dig Dis Sci 2013;58:2691-704. [PMID: 23720196 DOI: 10.1007/s10620-013-2705-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
299 Strassburg CP. [Patient selection and indications for liver transplantation]. Chirurg. 2013;84:363-371. [PMID: 23576124 DOI: 10.1007/s00104-012-2418-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
300 Rauchfuss F, Scheuerlein H, Götz M, Dittmar Y, Voigt R, Heise M, Settmacher U. [Hepatocellular carcinoma and cholangiocarcinoma]. Chirurg 2010;81:941-52; quiz 953. [PMID: 20827454 DOI: 10.1007/s00104-009-1864-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
301 Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, Takizawa S, Tsuchiya S, Tsujimoto G, Uemoto S, Shimizu K. MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One. 2011;6:e16435. [PMID: 21298008 DOI: 10.1371/journal.pone.0016435] [Cited by in Crossref: 90] [Cited by in F6Publishing: 78] [Article Influence: 9.0] [Reference Citation Analysis]
302 Hsu CY, Liu PH, Ho SY, Hsia CY, Kudaravalli P, Lee YH, Chiou YY, Tsai YJ, Huang YH, Huo TI. Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma. BMC Cancer 2018;18:289. [PMID: 29540157 DOI: 10.1186/s12885-018-4202-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
303 Lin CC, Chen CL. Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes. Hepatobiliary Surg Nutr 2016;5:415-21. [PMID: 27826556 DOI: 10.21037/hbsn.2016.08.02] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
304 Krenzien F, Schmelzle M, Struecker B, Raschzok N, Benzing C, Jara M, Bahra M, Öllinger R, Sauer IM, Pascher A, Pratschke J, Andreou A. Liver Transplantation and Liver Resection for Cirrhotic Patients with Hepatocellular Carcinoma: Comparison of Long-Term Survivals. J Gastrointest Surg 2018;22:840-8. [PMID: 29363019 DOI: 10.1007/s11605-018-3690-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
305 Liu B, Teng F, Fu H, Guo WY, Shi XM, Ni ZJ, Gao XG, Ma J, Fu ZR, Ding GS. Excessive intraoperative blood loss independently predicts recurrence of hepatocellular carcinoma after liver transplantation. BMC Gastroenterol 2015;15:138. [PMID: 26472203 DOI: 10.1186/s12876-015-0364-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
306 Fan ST. Hepatocellular carcinoma--resection or transplant? Nat Rev Gastroenterol Hepatol 2012;9:732-7. [PMID: 22965432 DOI: 10.1038/nrgastro.2012.158] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
307 Reiter FP, Hadjamu NJ, Nagdyman N, Zachoval R, Mayerle J, De Toni EN, Kaemmerer H, Denk G. Congenital heart disease-associated liver disease: a narrative review. Cardiovasc Diagn Ther 2021;11:577-90. [PMID: 33968635 DOI: 10.21037/cdt-20-595] [Reference Citation Analysis]
308 Sarpel U, Ayo D, Lobach I, Xu R, Newman E. Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma. HPB (Oxford). 2012;14:741-745. [PMID: 23043662 DOI: 10.1111/j.1477-2574.2012.00507.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
309 Clayton EF, Malik S, Bonnel A, Mu Y, Olthoff K, Shaked A, Abt PL, Peterman H, Rajender Reddy K, Ottmann S, Furth EE, Levine MH. Liver transplantation and cirrhotomimetic hepatocellular carcinoma: classification and outcomes. Liver Transpl. 2014;20:765-774. [PMID: 24668931 DOI: 10.1002/lt.23876] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
310 Wáng YX, De Baere T, Idée JM, Ballet S. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res 2015;27:96-121. [PMID: 25937772 DOI: 10.3978/j.issn.1000-9604.2015.03.03] [Cited by in F6Publishing: 29] [Reference Citation Analysis]
311 Jeong YH, Hwang S, Lee GD, Choi SH, Kim HR, Kim YH, Park SI, Kim DK. Surgical Outcome of Pulmonary Metastasectomy for Hepatocellular Carcinoma Recurrence in Liver Transplant Patients. Ann Transplant 2021;26:e930383. [PMID: 33972494 DOI: 10.12659/AOT.930383] [Reference Citation Analysis]
312 Choi TW, Kim HC, Lee JH, Yu SJ, Kang B, Hur S, Lee M, Jae HJ, Chung JW. The Safety and Clinical Outcomes of Chemoembolization in Child-Pugh Class C Patients with Hepatocellular Carcinomas. Korean J Radiol. 2015;16:1283-1293. [PMID: 26576118 DOI: 10.3348/kjr.2015.16.6.1283] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
313 Sourianarayanane A, El-Gazzaz G, Sanabria JR, Menon KV, Quintini C, Hashimoto K, Kelly D, Eghtesad B, Miller C, Fung J, Aucejo F. Loco-regional therapy in patients with Milan Criteria-compliant hepatocellular carcinoma and short waitlist time to transplant: An outcome analysis. HPB (Oxford). 2012;14:325-332. [PMID: 22487070 DOI: 10.1111/j.1477-2574.2012.00453.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
314 Liu Y, Zhao L, Ma W, Cao X, Chen H, Feng D, Liang J, Yin K, Jiang X. The Blockage of KCa3.1 Channel Inhibited Proliferation, Migration and Promoted Apoptosis of Human Hepatocellular Carcinoma Cells. J Cancer 2015;6:643-51. [PMID: 26078795 DOI: 10.7150/jca.11913] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
315 Singal AG, Tiro JA, Gupta S. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol. 2013;11:472-477. [PMID: 23200983 DOI: 10.1016/j.cgh.2012.11.010] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
316 Chuang YH, Ou HY, Yu CY, Chen CL, Weng CC, Tsang LL, Hsu HW, Lim WX, Huang TL, Cheng YF. Diffusion-weighted imaging for identifying patients at high risk of tumor recurrence following liver transplantation. Cancer Imaging 2019;19:74. [PMID: 31730015 DOI: 10.1186/s40644-019-0264-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
317 Kogure T, Ueno Y, Kawagishi N, Kanno N, Yamagiwa Y, Fukushima K, Satomi S, Shimosegawa T. The model for end-stage liver disease score is useful for predicting economic outcomes in adult cases of living donor liver transplantation. J Gastroenterol 2006;41:1005-10. [PMID: 17096070 DOI: 10.1007/s00535-006-1887-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
318 Ward EM, Sherif AE, O'Neill S, Hughes M, Ireland H, Wigmore SJ, Adair A. Clinical Outcomes of Ablation Compared with Resection for Single Hepatocellular Carcinoma Lesions, as a Primary Treatment or Bridging to Liver Transplantation: A Retrospective Comparative Study. Ann Transplant 2021;26:e931980. [PMID: 34326301 DOI: 10.12659/AOT.931980] [Reference Citation Analysis]
319 Ito T, Ishii T, Sumiyoshi S, Ogiso S, Fukumitsu K, Ito T, Yagi S, Seo S, Hata K, Taura K, Uemoto S. Living donor liver transplantation for combined hepatocellular-cholangiocarcinoma: A case series of four patients. Int J Surg Case Rep 2020;74:46-52. [PMID: 32791447 DOI: 10.1016/j.ijscr.2020.07.069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
320 Takada H, Tsuchiya K, Yasui Y, Nakakuki N, Tamaki N, Suzuki S, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Asahina Y, Enomoto N, Izumi N. Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Cancer Med 2016;5:3111-20. [PMID: 27748052 DOI: 10.1002/cam4.932] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
321 Wan P, Zhang JJ, Li QG, Xu N, Zhang M, Chen XS, Han LZ, Xia Q. Living-donor or deceased-donor liver transplantation for hepatic carcinoma: a case-matched comparison. World J Gastroenterol 2014;20:4393-400. [PMID: 24764678 DOI: 10.3748/wjg.v20.i15.4393] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
322 Rahman A, Assifi MM, Pedroso FE, Maley WR, Sola JE, Lavu H, Winter JM, Yeo CJ, Koniaris LG. Is resection equivalent to transplantation for early cirrhotic patients with hepatocellular carcinoma? A meta-analysis. J Gastrointest Surg. 2012;16:1897-1909. [PMID: 22836922 DOI: 10.1007/s11605-012-1973-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
323 Obed A, Beham A, Püllmann K, Becker H, Schlitt HJ, Lorf T. Patients without hepatocellular carcinoma progression after transarterial chemoembolization benefit from liver transplantation. World J Gastroenterol 2007;13:761-7. [PMID: 17278200 DOI: 10.3748/wjg.v13.i5.761] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
324 Maegawa FB, Shehorn L, Aziz H, Kettelle J, Jie T, Riall TS. Association Between Noninvasive Fibrosis Markers and Postoperative Mortality After Hepatectomy for Hepatocellular Carcinoma. JAMA Netw Open 2019;2:e187142. [PMID: 30657533 DOI: 10.1001/jamanetworkopen.2018.7142] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
325 Hernández-Guerra M, Hernández-Camba A, Turnes J, Ramos LM, Arranz L, Mera J, Crespo J, Quintero E. Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival. United European Gastroenterol J 2015;3:284-93. [PMID: 26279838 DOI: 10.1177/2050640615575971] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
326 Fujita K, Iwama H, Miyoshi H, Tani J, Oura K, Tadokoro T, Sakamoto T, Nomura T, Morishita A, Yoneyama H, Masaki T. Diabetes mellitus and metformin in hepatocellular carcinoma. World J Gastroenterol 2016;22:6100-13. [PMID: 27468203 DOI: 10.3748/wjg.v22.i27.6100] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
327 Dueland S, Line PD, Hagness M, Foss A, Andersen MH. Long-term quality of life after liver transplantation for non-resectable colorectal metastases confined to the liver. BJS Open 2019;3:180-5. [PMID: 30957065 DOI: 10.1002/bjs5.50116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
328 Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:293-313. [PMID: 33510460 DOI: 10.1038/s41575-020-00395-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
329 Caturelli E, Solmi L, Anti M, Fusilli S, Roselli P, Andriulli A, Fornari F, Del Vecchio Blanco C, de Sio I. Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut. 2004;53:1356-1362. [PMID: 15306600 DOI: 10.1136/gut.2003.032359] [Cited by in Crossref: 93] [Cited by in F6Publishing: 77] [Article Influence: 5.5] [Reference Citation Analysis]
330 Koniaris LG, Levi DM, Pedroso FE, Franceschi D, Tzakis AG, Santamaria-Barria JA, Tang J, Anderson M, Misra S, Solomon NL, Jin X, DiPasco PJ, Byrne MM, Zimmers TA. Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma? Ann Surg 2011;254:527-37; discussion 537-8. [PMID: 21865950 DOI: 10.1097/SLA.0b013e31822ca66f] [Cited by in Crossref: 77] [Cited by in F6Publishing: 33] [Article Influence: 7.7] [Reference Citation Analysis]
331 Braat MN, Samim M, van den Bosch MA, Lam MG. The role of 90Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review. Clin Transl Imaging 2016;4:283-95. [PMID: 27512689 DOI: 10.1007/s40336-016-0172-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
332 Jarnagin W, Chapman WC, Curley S, D'Angelica M, Rosen C, Dixon E, Nagorney D;  American Hepato-Pancreato-Biliary Association;  Society of Surgical Oncology;  Society for Surgery of the Alimentary Tract. Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford). 2010;12:302-310. [PMID: 20590903 DOI: 10.1111/j.1477-2574.2010.00182.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 7.1] [Reference Citation Analysis]
333 Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol. 2014;20:10223-10237. [PMID: 25132740 DOI: 10.3748/wjg.v20.i30.10223] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
334 Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence based treatment. World J Gastroenterol. 2014;20:5442-5460. [PMID: 24833875 DOI: 10.3748/wjg.v20.i18.5442] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 66] [Article Influence: 14.5] [Reference Citation Analysis]
335 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 593] [Article Influence: 345.0] [Reference Citation Analysis]
336 Bodzin AS, Busuttil RW. Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. World J Hepatol. 2015;7:1157-1167. [PMID: 26019732 DOI: 10.4254/wjh.v7.i9.1157] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 8.2] [Reference Citation Analysis]
337 Fisher RA, Kulik LM, Freise CE, Lok AS, Shearon TH, Brown RS Jr, Ghobrial RM, Fair JH, Olthoff KM, Kam I, Berg CL; A2ALL Study Group. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant. 2007;7:1601-1608. [PMID: 17511683 DOI: 10.1111/j.1600-6143.2007.01802.x] [Cited by in Crossref: 175] [Cited by in F6Publishing: 157] [Article Influence: 12.5] [Reference Citation Analysis]
338 Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver cancer: Approaching a personalized care. J Hepatol 2015;62:S144-56. [PMID: 25920083 DOI: 10.1016/j.jhep.2015.02.007] [Cited by in Crossref: 136] [Cited by in F6Publishing: 123] [Article Influence: 27.2] [Reference Citation Analysis]
339 Lorente L, Rodriguez ST, Sanz P, Pérez-Cejas A, Padilla J, Díaz D, González A, Martín MM, Jiménez A, Barrera MA. Prognostic Value of Serum Caspase-Cleaved Cytokeratin-18 Levels before Liver Transplantation for One-Year Survival of Patients with Hepatocellular Carcinoma. Int J Mol Sci 2016;17:E1524. [PMID: 27618033 DOI: 10.3390/ijms17091524] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
340 Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology 2019;69:1193-205. [PMID: 30548884 DOI: 10.1002/hep.30413] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
341 Shrestha R, Prithviraj P, Anaka M, Bridle KR, Crawford DHG, Dhungel B, Steel JC, Jayachandran A. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma. Front Oncol. 2018;8:269. [PMID: 30057891 DOI: 10.3389/fonc.2018.00269] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 12.7] [Reference Citation Analysis]
342 Groeschl RT, Hong JC, Christians KK, Turaga KK, Tsai S, Pilgrim CH, Gamblin TC. Viral status at the time of liver transplantation for hepatocellular carcinoma: a modern predictor of longterm survival. HPB (Oxford) 2013;15:794-802. [PMID: 23782341 DOI: 10.1111/hpb.12134] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
343 Zeair S, Rajchert J, Stasiuk R, Cyprys S, Miętkiewski J, Zasada-Cedro K, Karpińska E, Duczkowska M, Parczewski M, Wawrzynowicz-Syczewska M. Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Single-Center Experience. Ann Transplant 2019;24:499-505. [PMID: 31439828 DOI: 10.12659/AOT.918150] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
344 Herden U, Schoening W, Pratschke J, Manekeller S, Paul A, Linke R, Lorf T, Lehner F, Braun F, Stippel DL, Sucher R, Schmidt H, Strassburg CP, Guba M, van Rosmalen M, Rogiers X, Samuel U, Schön GM, Nashan B. Accuracy of Pretransplant Imaging Diagnostic for Hepatocellular Carcinoma: A Retrospective German Multicenter Study. Can J Gastroenterol Hepatol 2019;2019:8747438. [PMID: 30949459 DOI: 10.1155/2019/8747438] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
345 Xu XS, Wan Y, Song SD, Chen W, Miao RC, Zhou YY, Zhang LQ, Qu K, Liu SN, Zhang YL, Dong YF, Liu C. Model based on γ-glutamyltransferase and alkaline phosphatase for hepatocellular carcinoma prognosis. World J Gastroenterol 2014;20:10944-52. [PMID: 25152598 DOI: 10.3748/wjg.v20.i31.10944] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
346 Xu M, Doyle MM, Banan B, Vachharajani N, Wang X, Saad N, Fowler K, Brunt EM, Lin Y, Chapman WC. Neoadjuvant Locoregional Therapy and Recurrent Hepatocellular Carcinoma after Liver Transplantation. J Am Coll Surg. 2017;225:28-40. [PMID: 28400300 DOI: 10.1016/j.jamcollsurg.2017.03.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
347 Moris D, Kostakis ID, Machairas N, Prodromidou A, Tsilimigras DI, Ravindra KV, Sudan DL, Knechtle SJ, Barbas AS. Comparison between liver transplantation and resection for hilar cholangiocarcinoma: A systematic review and meta-analysis. PLoS One. 2019;14:e0220527. [PMID: 31365594 DOI: 10.1371/journal.pone.0220527] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
348 Poulou LS, Botsa E, Thanou I, Ziakas PD, Thanos L. Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Hepatol 2015;7:1054-63. [PMID: 26052394 DOI: 10.4254/wjh.v7.i8.1054] [Cited by in Crossref: 150] [Cited by in F6Publishing: 109] [Article Influence: 25.0] [Reference Citation Analysis]
349 Song AT, Avelino-Silva VI, Pecora RA, Pugliese V, D'Albuquerque LA, Abdala E. Liver transplantation: fifty years of experience. World J Gastroenterol. 2014;20:5363-5374. [PMID: 24833866 DOI: 10.3748/wjg.v20.i18.5363] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 29] [Article Influence: 7.7] [Reference Citation Analysis]
350 Puigvehí M, Hashim D, Haber PK, Dinani A, Schiano TD, Asgharpour A, Kushner T, Kakked G, Tabrizian P, Schwartz M, Gurakar A, Dieterich D, Boffetta P, Friedman SL, Llovet JM, Saberi B. Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. Am J Transplant 2020;20:220-30. [PMID: 31437349 DOI: 10.1111/ajt.15576] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
351 Dormandy TL, Munro JG. Oxyhaemoglobin without oxygen. Nature. 1965;206:410-411. [PMID: 4284287 DOI: 10.1016/j.jceh.2014.05.004] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 0.7] [Reference Citation Analysis]
352 Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M, Miller CM, Schwartz ME. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002;235:533-9. [PMID: 11923610 DOI: 10.1097/00000658-200204000-00012] [Cited by in Crossref: 322] [Cited by in F6Publishing: 286] [Article Influence: 16.9] [Reference Citation Analysis]
353 Kim JH, Sinn DH, Gwak GY, Choi GS, Kim JM, Kwon CHD, Joh JW, Kim KY, Kim K, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Factors determining long-term outcomes of hepatocellular carcinoma within the Milan criteria: liver transplantation versus locoregional therapy: A retrospective cohort study. Medicine (Baltimore) 2016;95:e4735. [PMID: 27583916 DOI: 10.1097/MD.0000000000004735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
354 Yang B, You X, Yuan ML, Qin TQ, Duan LJ, He J, Fei ZJ, Zhou X, Zan RY, Liao ZY. Transarterial Ethanol Ablation Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Hepat Mon. 2016;16:e37584. [PMID: 27799963 DOI: 10.5812/hepatmon.37584] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
355 Zhang W, Liu C, Tan Y, Tan L, Jiang L, Yang J, Yang J, Yan L, Wen T. Albumin-Bilirubin Score for Predicting Post-Transplant Complications Following Adult-to-Adult Living Donor Liver Transplantation. Ann Transplant 2018;23:639-46. [PMID: 30201946 DOI: 10.12659/AOT.910824] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 3.3] [Reference Citation Analysis]
356 Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF, Carrillo-Pérez DL. Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol 2015;7:362-76. [PMID: 25848464 DOI: 10.4254/wjh.v7.i3.362] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 11.7] [Reference Citation Analysis]
357 Sanuki N, Takeda A, Kunieda E. Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol. 2014;20:3100-3111. [PMID: 24696597 DOI: 10.3748/wjg.v20.i12.3100] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 37] [Article Influence: 7.7] [Reference Citation Analysis]
358 Biselli M, Garuti F, Neri A. Hepatocellular carcinoma surveillance: an open question. Hepatobiliary Surg Nutr 2019;8:431-2. [PMID: 31489324 DOI: 10.21037/hbsn.2019.02.10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
359 Roderburg C, Bubenzer J, Spannbauer M, do O N, Mahnken A, Ludde T, Trautwein C, Tischendorf JJ. Long-term survival of a HCC-patient with severe liver dysfunction treated with sorafenib. World J Hepatol 2010;2:239-42. [PMID: 21161003 DOI: 10.4254/wjh.v2.i6.239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
360 Luzi L, Perseghin G, Regalia E, Sereni LP, Battezzati A, Baratti D, Bianchi E, Terruzzi I, Hilden H, Groop LC. Metabolic effects of liver transplantation in cirrhotic patients. J Clin Invest. 1997;99:692-700. [PMID: 9045872 DOI: 10.1172/jci119213] [Cited by in Crossref: 37] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
361 DuBay DA, Sandroussi C, Kachura JR, Ho CS, Beecroft JR, Vollmer CM, Ghanekar A, Guba M, Cattral MS, McGilvray ID. Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HPB (Oxford). 2011;13:24-32. [PMID: 21159100 DOI: 10.1111/j.1477-2574.2010.00228.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
362 Miao W, Nie P, Yang G, Wang Y, Yan L, Zhao Y, Yu T, Yu M, Wu F, Rao W, Wang Z. An FDG PET/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation. Eur J Nucl Med Mol Imaging 2021. [PMID: 33813592 DOI: 10.1007/s00259-021-05328-w] [Reference Citation Analysis]
363 Panayotova G, Lunsford KE, Latt NL, Paterno F, Guarrera JV, Pyrsopoulos N. Expanding indications for liver transplantation in the era of liver transplant oncology. World J Gastrointest Surg 2021;13:392-405. [PMID: 34122730 DOI: 10.4240/wjgs.v13.i5.392] [Reference Citation Analysis]
364 Tsai N, Jeffers L, Cragin L, Sorensen S, Su W, Rosenblatt L, Tang H, Hebden T, Juday T. Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective. Clinicoecon Outcomes Res. 2012;4:227-235. [PMID: 22977309 DOI: 10.2147/ceor.s31784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
365 Gassmann P, Spieker T, Haier J, Schmidt F, Mardin WA, Senninger N. Prognostic impact of underlying liver fibrosis and cirrhosis after curative resection of hepatocellular carcinoma. World J Surg 2010;34:2442-51. [PMID: 20544346 DOI: 10.1007/s00268-010-0655-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
366 Zheng J, Xie W, Huang Y, Zhu Y, Jiang L. The technique of 3D reconstruction combining with biochemistry to build an equivalent formula of indocyanine green (ICG) clearance test to assess the liver reserve function. BMC Surg 2020;20:283. [PMID: 33183305 DOI: 10.1186/s12893-020-00952-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
367 Morioka D, Egawa H, Kasahara M, Ito T, Haga H, Takada Y, Shimada H, Tanaka K. Outcomes of adult-to-adult living donor liver transplantation: a single institution’s experience with 335 consecutive cases. Ann Surg. 2007;245:315-325. [PMID: 17245187 DOI: 10.1097/01.sla.0000236600.24667.a4] [Cited by in Crossref: 140] [Cited by in F6Publishing: 119] [Article Influence: 10.0] [Reference Citation Analysis]
368 Eghtesad B, Aucejo F. Liver transplantation for malignancies. J Gastrointest Cancer. 2014;45:353-362. [PMID: 24604263 DOI: 10.1007/s12029-014-9590-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
369 Pitton MB, Kloeckner R, Herber S, Otto G, Kreitner KF, Dueber C. MRI versus 64-row MDCT for diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009;15:6044-51. [PMID: 20027676 DOI: 10.3748/wjg.15.6044] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
370 Zhang A, Yin C, Wang Z, Zhang Y, Zhao Y, Li A, Sun H, Lin D, Li N. Development and application of a fluorescence protein microarray for detecting serum alpha-fetoprotein in patients with hepatocellular carcinoma. J Int Med Res 2016;44:1414-23. [PMID: 27885040 DOI: 10.1177/0300060516672370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
371 Cho Y, Lee DH, Lee YB, Lee M, Yoo JJ, Choi WM, Cho YY, Paeng JC, Kang KW, Chung JK, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim YJ. Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma? PLoS One 2014;9:e105679. [PMID: 25153834 DOI: 10.1371/journal.pone.0105679] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
372 Duda DG, Dima SO, Cucu D, Sorop A, Klein S, Ancukiewicz M, Kitahara S, Iacob S, Bacalbasa N, Tomescu D, Herlea V, Tanase C, Croitoru A, Popescu I. Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients. Cancers (Basel) 2020;12:E1275. [PMID: 32443546 DOI: 10.3390/cancers12051275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
373 Lambert B, Van de Wiele C. Treatment of hepatocellular carcinoma by means of radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2005;32:980-989. [PMID: 16032439 DOI: 10.1007/s00259-005-1859-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
374 Kornberg A, Friess H. 18F-fludeoxyglucose positron emission tomography for diagnosis of HCC: implications for therapeutic strategy in curative and non-curative approaches. Therap Adv Gastroenterol 2019;12:1756284819836205. [PMID: 30915167 DOI: 10.1177/1756284819836205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
375 Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, Hirose R, Fidelman N, Kerlan RK Jr, Roberts JP. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61:1968-1977. [PMID: 25689978 DOI: 10.1002/hep.27752] [Cited by in Crossref: 217] [Cited by in F6Publishing: 160] [Article Influence: 36.2] [Reference Citation Analysis]
376 Au JS, Frenette CT. Management of Hepatocellular Carcinoma: Current Status and Future Directions. Gut Liver. 2015;9:437-448. [PMID: 26087860 DOI: 10.5009/gnl15022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
377 Tong MJ, Rosinski AA, Huynh CT, Raman SS, Lu DSK. Long-term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma. Hepatol Commun 2017;1:595-608. [PMID: 29404481 DOI: 10.1002/hep4.1047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
378 Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation. Liver Transpl 2018;24:1346-56. [PMID: 30067889 DOI: 10.1002/lt.25317] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 11.5] [Reference Citation Analysis]
379 Li Y, Liu X, Jiang Y, Wan K, Liu W, Ou Y, Bai J, You Y, Hu F, Xu Z, Bie P, Zhang C, Zhang L. Low preoperative prealbumin predicts the prevalence of complications following liver transplantation. BMC Gastroenterol 2021;21:233. [PMID: 34022800 DOI: 10.1186/s12876-021-01818-1] [Reference Citation Analysis]
380 Chen JW, Kow L, Verran DJ, McCall JL, Munn S, Balderson GA, Fawcett JW, Gow PJ, Jones RM, Jeffrey GP. Poorer survival in patients whose explanted hepatocellular carcinoma (HCC) exceeds Milan or UCSF Criteria. An analysis of liver transplantation in HCC in Australia and New Zealand. HPB (Oxford). 2009;11:81-89. [PMID: 19590628 DOI: 10.1111/j.1477-2574.2009.00022.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
381 Najjar M, Agrawal S, Emond JC, Halazun KJ. Pretreatment neutrophil-lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma. J Hepatocell Carcinoma. 2018;5:17-28. [PMID: 29404284 DOI: 10.2147/jhc.s86792] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
382 Dubash SR, Idowu OA, Sharma R. The emerging role of positron emission tomography in hepatocellular carcinoma. Hepat Oncol. 2015;2:191-200. [PMID: 30190998 DOI: 10.2217/hep.15.6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
383 Wang M, Shen J, Herrera H, Singal A, Swindell C, Renquan L, Mehta A. Biomarker analysis of fucosylated kininogen through depletion of lectin reactive heterophilic antibodies in hepatocellular carcinoma. J Immunol Methods 2018;462:59-64. [PMID: 30144410 DOI: 10.1016/j.jim.2018.08.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
384 Untereiner X, Cagniet A, Memeo R, Cherkaoui Z, Piardi T, Severac F, Mutter D, Kianmanesh R, Wakabayashi T, Sommacale D, Pessaux P. Laparoscopic Hepatectomy Versus Open Hepatectomy for the Management of Hepatocellular Carcinoma: A Comparative Study Using a Propensity Score Matching. World J Surg 2019;43:615-25. [PMID: 30341471 DOI: 10.1007/s00268-018-4827-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
385 Hasegawa K, Kokudo N, Imamura H, Matsuyama Y, Aoki T, Minagawa M, Sano K, Sugawara Y, Takayama T, Makuuchi M. Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg. 2005;242:252-259. [PMID: 16041216 DOI: 10.1097/01.sla.0000171307.37401.db] [Cited by in Crossref: 452] [Cited by in F6Publishing: 384] [Article Influence: 28.3] [Reference Citation Analysis]
386 Zhao JD, Liu J, Ren ZG, Gu K, Zhou ZH, Li WT, Chen Z, Xu ZY, Liu LM, Jiang GL. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study. Radiat Oncol. 2010;5:12. [PMID: 20149262 DOI: 10.1186/1748-717X-5-12] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
387 Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore). 2017;96:e5904. [PMID: 28248853 DOI: 10.1097/md.0000000000005904] [Cited by in Crossref: 74] [Cited by in F6Publishing: 47] [Article Influence: 18.5] [Reference Citation Analysis]
388 Sotiropoulos GC, Radtke A, Schmitz KJ, Molmenti EP, Schroeder T, Saner FH, Baba HA, Fouzas I, Broelsch CE, Malagó M. Liver transplantation in the setting of hepatocellular carcinoma and portal vein thrombosis: a challenging dilemma? Dig Dis Sci. 2008;53:1994-1999. [PMID: 18080191 DOI: 10.1007/s10620-007-0099-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
389 Leung C, Yeoh SW, Patrick D, Ket S, Marion K, Gow P, Angus PW. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol. 2015;21:1189-1196. [PMID: 25632192 DOI: 10.3748/wjg.v21.i4.1189] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 58] [Article Influence: 11.0] [Reference Citation Analysis]
390 Belghiti J, Cortes A, Abdalla EK, Régimbeau JM, Prakash K, Durand F, Sommacale D, Dondero F, Lesurtel M, Sauvanet A. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg. 2003;238:885-892; discussion 892-893. [PMID: 14631225 DOI: 10.1097/01.sla.0000098621.74851.65] [Cited by in Crossref: 313] [Cited by in F6Publishing: 272] [Article Influence: 17.4] [Reference Citation Analysis]
391 Hung HH, Lei HJ, Chau GY, Su CW, Hsia CY, Kao WY, Lui WY, Wu WC, Lin HC, Wu JC. Milan criteria, multi-nodularity, and microvascular invasion predict the recurrence patterns of hepatocellular carcinoma after resection. J Gastrointest Surg. 2013;17:702-711. [PMID: 23225107 DOI: 10.1007/s11605-012-2087-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
392 Chang CM, Yin WY, Su YC, Wei CK, Lee CH, Juang SY, Chen YT, Chen JC, Lee CC. Preoperative risk score predicting 90-day mortality after liver resection in a population-based study. Medicine (Baltimore) 2014;93:e59. [PMID: 25211044 DOI: 10.1097/MD.0000000000000059] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
393 Sun L, Wu H, Guan YS. Positron emission tomography/computer tomography: challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies. World J Gastroenterol 2007;13:2775-83. [PMID: 17569111 DOI: 10.3748/wjg.v13.i20.2775] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
394 Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6:1418-1424. [PMID: 18848905 DOI: 10.1016/j.cgh.2008.08.005] [Cited by in Crossref: 139] [Cited by in F6Publishing: 112] [Article Influence: 10.7] [Reference Citation Analysis]
395 Chen LC, Lin HY, Hung SK, Chiou WY, Lee MS. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World J Gastroenterol 2021;27:2434-57. [PMID: 34092968 DOI: 10.3748/wjg.v27.i20.2434] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
396 Lang H, Heinrich S, Bartsch F, Hüttl F, Baumgart J, Mittler J. [Surgical treatment of hepatic tumors-liver resection and transplantation]. Internist (Berl) 2020;61:147-57. [PMID: 32016491 DOI: 10.1007/s00108-020-00754-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
397 Bergquist JR, Li AY, Javadi CS, Chima RS, Frye JS, Visser BC. Too Big to Fail: Successful Resection of a Large Hepatocellular Carcinoma with Portal Tumor Thrombus. Dig Dis Sci 2021;66:1797-801. [PMID: 33140182 DOI: 10.1007/s10620-020-06682-9] [Reference Citation Analysis]
398 Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Mulcahy MF. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol. 2011;54:695-704. [PMID: 21147504 DOI: 10.1016/j.jhep.2010.10.004] [Cited by in Crossref: 124] [Cited by in F6Publishing: 104] [Article Influence: 11.3] [Reference Citation Analysis]
399 Lim C, Mise Y, Sakamoto Y, Yamamoto S, Shindoh J, Ishizawa T, Aoki T, Hasegawa K, Sugawara Y, Makuuchi M. Above 5 cm, size does not matter anymore in patients with hepatocellular carcinoma. World J Surg. 2014;38:2910-2918. [PMID: 25099682 DOI: 10.1007/s00268-014-2704-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
400 Liang BY, Gu J, Xiong M, Zhang EL, Zhang ZY, Chen XP, Huang ZY. Tumor size may influence the prognosis of solitary hepatocellular carcinoma patients with cirrhosis and without macrovascular invasion after hepatectomy. Sci Rep 2021;11:16343. [PMID: 34381132 DOI: 10.1038/s41598-021-95835-5] [Reference Citation Analysis]
401 Torres HA, Mahale P, Miller ED, Oo TH, Frenette C, Kaseb AO. Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma. World J Hepatol 2013;5:332-5. [PMID: 23805358 DOI: 10.4254/wjh.v5.i6.332] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
402 Tan CHN, Yu Y, Tan YRN, Lim BLK, Iyer SG, Madhavan K, Kow AWC. Bridging therapies to liver transplantation for hepatocellular carcinoma: A bridge to nowhere? Ann Hepatobiliary Pancreat Surg 2018;22:27-35. [PMID: 29536053 DOI: 10.14701/ahbps.2018.22.1.27] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
403 Sapisochin G, de Sevilla EF, Echeverri J, Charco R. Management of “very early” hepatocellular carcinoma on cirrhotic patients. World J Hepatol. 2014;6:766-775. [PMID: 25429314 DOI: 10.4254/wjh.v6.i11.766] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
404 Shao Z, Lopez R, Shen B, Yang GS. Orthotopic liver transplantation as a rescue operation for recurrent hepatocellular carcinoma after partial hepatectomy. World J Gastroenterol 2008;14:4370-6. [PMID: 18666328 DOI: 10.3748/wjg.14.4370] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
405 Kokudo N, Makuuchi M. Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol 2009;44 Suppl 19:119-21. [PMID: 19148805 DOI: 10.1007/s00535-008-2244-z] [Cited by in Crossref: 86] [Cited by in F6Publishing: 84] [Article Influence: 7.2] [Reference Citation Analysis]
406 Ma KW, Chok KSH, Fung JYY, Lo CM. Liver Transplantation for Hepatitis B Virus-related Hepatocellular Carcinoma in Hong Kong. J Clin Transl Hepatol 2018;6:283-8. [PMID: 30271740 DOI: 10.14218/JCTH.2017.00058] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
407 Shetty K, Dash C, Laurin J. Use of adjuvant sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma. J Transplant 2014;2014:913634. [PMID: 24818010 DOI: 10.1155/2014/913634] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
408 Meriggi F, Graffeo M. Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. Cancers (Basel) 2021;13:584. [PMID: 33540870 DOI: 10.3390/cancers13030584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
409 Riaz A, Awais R, Salem R. Side effects of yttrium-90 radioembolization. Front Oncol. 2014;4:198. [PMID: 25120955 DOI: 10.3389/fonc.2014.00198] [Cited by in Crossref: 75] [Cited by in F6Publishing: 48] [Article Influence: 10.7] [Reference Citation Analysis]
410 Al-Busafi SA, Al-Shuaili H, Omar H, Al-Zuhaibi H, Jeyaseelan L, Al-Naamani K. Epidemiology of Chronic Hepatitis C Infections at a Tertiary Care Centre in Oman. Sultan Qaboos Univ Med J 2017;17:e404-10. [PMID: 29372081 DOI: 10.18295/squmj.2017.17.04.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
411 Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, Marasco G, Festi D. Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol 2014;20:5935-50. [PMID: 24876717 DOI: 10.3748/wjg.v20.i20.5935] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 84] [Article Influence: 13.7] [Reference Citation Analysis]
412 Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY. Alpha-Fetoprotein Slope; 7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma. Transplantation. 2018;102:816-822. [PMID: 29505494 DOI: 10.1097/tp.0000000000002094] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
413 Cauchy F, Fuks D, Belghiti J. HCC: current surgical treatment concepts. Langenbecks Arch Surg 2012;397:681-95. [DOI: 10.1007/s00423-012-0911-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
414 Rubinstein MM, Kaubisch A, Kinkhabwala M, Reinus J, Liu Q, Chuy JW. Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation. J Gastrointest Oncol 2017;8:1051-5. [PMID: 29299366 DOI: 10.21037/jgo.2017.08.11] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
415 Choi YR, Chung JW, Kim JH, Kim HC, Jae HJ, Hur S. Cone-Beam Computed Tomography-Hepatic Arteriography as a Diagnostic Tool for Small Hypervascular Hepatocellular Carcinomas: Method and Clinical Implications. Korean J Radiol 2020;21:306-15. [PMID: 32090523 DOI: 10.3348/kjr.2019.0060] [Reference Citation Analysis]
416 Saito R, Amemiya H, Hosomura N, Kawaida H, Maruyama S, Shimizu H, Furuya S, Akaike H, Kawaguchi Y, Sudo M, Inoue S, Kono H, Ichikawa D. Prognostic Significance of Treatment Strategies for the Recurrent Hepatocellular Carcinomas After Radical Resection. In Vivo 2020;34:1265-70. [PMID: 32354917 DOI: 10.21873/invivo.11900] [Reference Citation Analysis]
417 Facciuto ME, Rochon C, Pandey M, Rodriguez-Davalos M, Samaniego S, Wolf DC, Kim-Schluger L, Rozenblit G, Sheiner PA. Surgical dilemma: liver resection or liver transplantation for hepatocellular carcinoma and cirrhosis. Intention-to-treat analysis in patients within and outwith Milan criteria. HPB (Oxford) 2009;11:398-404. [PMID: 19768144 DOI: 10.1111/j.1477-2574.2009.00073.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 4.5] [Reference Citation Analysis]
418 Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP, Guindi M, Porter G, Kachura JR, Rasuli P, Gill S, Ghali P, Chaudhury P, Siddiqui J, Valenti D, Weiss A, Wong R. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol 2011;18:228-40. [PMID: 21980250 DOI: 10.3747/co.v18i5.952] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
419 Pinheiro RS, Waisberg DR, Nacif LS, Rocha-Santos V, Arantes RM, Ducatti L, Martino RB, Lai Q, Andraus W, D'Albuquerque LAC. Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure? Transl Gastroenterol Hepatol 2017;2:68. [PMID: 28905009 DOI: 10.21037/tgh.2017.08.02] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
420 Tschirch FT, Struwe A, Petrowsky H, Kakales I, Marincek B, Weishaupt D. Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol. 2008;18:1577-1586. [PMID: 18369632 DOI: 10.1007/s00330-008-0929-6] [Cited by in Crossref: 132] [Cited by in F6Publishing: 114] [Article Influence: 10.2] [Reference Citation Analysis]
421 Xu G, Jin B, Xian X, Yang H, Zhao H, Du S, Makuuchi M, Pawlik TM, Mao Y. Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field. Liver Cancer 2021;10:137-50. [PMID: 33977090 DOI: 10.1159/000513412] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
422 Poynard T, Peta V, Deckmyn O, Munteanu M, Moussalli J, Ngo Y, Rudler M, Lebray P, Pais R, Bonyhay L, Charlotte F, Thibault V, Fartoux L, Lucidarme O, Eyraud D, Scatton O, Savier E, Valantin MA, Ngo A, Drane F, Rosmorduc O, Imbert-Bismut F, Housset C, Thabut D, Ratziu V; HECAM-FibroFrance Group. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Aliment Pharmacol Ther 2019;49:308-20. [PMID: 30569507 DOI: 10.1111/apt.15082] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
423 Yanik EL, Chinnakotla S, Gustafson SK, Snyder JJ, Israni AK, Segev DL, Engels EA. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma. Liver Transpl 2016;22:627-34. [PMID: 26784951 DOI: 10.1002/lt.24395] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
424 Nanashima A, Masuda J, Miuma S, Sumida Y, Nonaka T, Tanaka K, Hidaka S, Sawai T, Nagayasu T. Selection of treatment modality for hepatocellular carcinoma according to the modified Japan Integrated Staging score. World J Gastroenterol 2008;14:58-63. [PMID: 18176962 DOI: 10.3748/wjg.14.58] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
425 Babusis D, Curry MP, Kirby B, Park Y, Murakami E, Wang T, Mathias A, Afdhal N, McHutchison JG, Ray AS. Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus. Antimicrob Agents Chemother 2018;62:e02587-17. [PMID: 29439971 DOI: 10.1128/AAC.02587-17] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
426 Digumarthy SR, Sahani DV, Saini S. MRI in detection of hepatocellular carcinoma (HCC). Cancer Imaging. 2005;5:20-24. [PMID: 16154814 DOI: 10.1102/1470-7330.2005.0005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
427 Beumer BR, de Wilde RF, Metselaar HJ, de Man RA, Polak WG, Ijzermans JNM. The Treatment Effect of Liver Transplantation versus Liver Resection for HCC: A Review and Future Perspectives. Cancers (Basel) 2021;13:3730. [PMID: 34359629 DOI: 10.3390/cancers13153730] [Reference Citation Analysis]
428 Esnaola NF, Lauwers GY, Mirza NQ, Nagorney DM, Doherty D, Ikai I, Yamaoka Y, Regimbeau JM, Belghiti J, Curley SA. Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg. 2002;6:224-232; discussion 232. [PMID: 11992808 DOI: 10.1016/s1091-255x(01)00015-4] [Cited by in Crossref: 177] [Cited by in F6Publishing: 58] [Article Influence: 9.3] [Reference Citation Analysis]
429 Ikai I, Yamaoka Y, Yamamoto Y, Ozaki N, Sakai Y, Satoh S, Shinkura N, Yamamoto M. Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis: proposal as a standard therapy. Ann Surg. 1998;227:433-439. [PMID: 9527067 DOI: 10.1097/00000658-199803000-00016] [Cited by in Crossref: 84] [Cited by in F6Publishing: 68] [Article Influence: 3.7] [Reference Citation Analysis]
430 Nicolini D, Svegliati-Baroni G, Candelari R, Mincarelli C, Mandolesi A, Bearzi I, Mocchegiani F, Vecchi A, Montalti R, Benedetti A, Risaliti A, Vivarelli M. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World J Gastroenterol 2013;19:5622-32. [PMID: 24039354 DOI: 10.3748/wjg.v19.i34.5622] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
431 Azzam AZ. Liver transplantation as a management of hepatocellular carcinoma. World J Hepatol 2015;7:1347-54. [PMID: 26052380 DOI: 10.4254/wjh.v7.i10.1347] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
432 Toshima T, Shirabe K, Takeishi K, Motomura T, Mano Y, Uchiyama H, Yoshizumi T, Soejima Y, Taketomi A, Maehara Y. New method for assessing liver fibrosis based on acoustic radiation force impulse: a special reference to the difference between right and left liver. J Gastroenterol. 2011;46:705-711. [PMID: 21264479 DOI: 10.1007/s00535-010-0365-7] [Cited by in Crossref: 86] [Cited by in F6Publishing: 84] [Article Influence: 8.6] [Reference Citation Analysis]
433 Chung JH, Ahn HS, Kim SG, Lee YN, Kim YS, Jeong SW, Jang JY, Lee SH, Kim HS, Kim BS. The usefulness of transient elastography, acoustic-radiation-force impulse elastography, and real-time elastography for the evaluation of liver fibrosis. Clin Mol Hepatol. 2013;19:156-164. [PMID: 23837140 DOI: 10.3350/cmh.2013.19.2.156] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
434 Kumaran V. Role of liver transplantation for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S97-S103. [PMID: 25755618 DOI: 10.1016/j.jceh.2014.01.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
435 Gounder PP, Bulkow LR, Meltzer MI, Bruce MG, Hennessy TW, Snowball M, Spradling PR, Adhikari BB, McMahon BJ. Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983-2012. Int J Circumpolar Health 2016;75:31115. [PMID: 27197711 DOI: 10.3402/ijch.v75.31115] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
436 Bednarsch J, Czigany Z, Heij LR, Liu D, den Dulk M, Wiltberger G, Bruners P, Ulmer TF, Neumann UP, Lang SA. Compelling Long-Term Results for Liver Resection in Early Cholangiocarcinoma. J Clin Med 2021;10:2959. [PMID: 34209368 DOI: 10.3390/jcm10132959] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
437 Frankova S, Lunova M, Gottfriedova H, Senkerikova R, Neroldova M, Kovac J, Kieslichova E, Lanska V, Urbanek P, Spicak J, Jirsa M, Sperl J. Liver stiffness measured by two-dimensional shear-wave elastography predicts hepatic vein pressure gradient at high values in liver transplant candidates with advanced liver cirrhosis. PLoS One 2021;16:e0244934. [PMID: 33411729 DOI: 10.1371/journal.pone.0244934] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
438 Kim DY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Shin SW, Choo SW, Do YS, Rhee JC. Milan criteria are useful predictors for favorable outcomes in hepatocellular carcinoma patients undergoing liver transplantation after transarterial chemoembolization. World J Gastroenterol 2006;12:6992-7. [PMID: 17109521 DOI: 10.3748/wjg.v12.i43.6992] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
439 Santos CA, Hotchkiss RS, Chapman WC, Olsen MA. Epidemiology of Bloodstream Infections in a Multicenter Retrospective Cohort of Liver Transplant Recipients. Transplant Direct 2016;2:e67. [PMID: 27458606 DOI: 10.1097/TXD.0000000000000573] [Cited by in Crossref: 9] [Article Influence: 1.8] [Reference Citation Analysis]
440 Radunz S, Treckmann J, Baba HA, Best J, Müller S, Theysohn JM, Paul A, Benkö T. Long-Term Outcome After Liver Transplantation for Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment. Ann Transplant 2017;22:215-21. [PMID: 28408731 DOI: 10.12659/aot.902595] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
441 Koh PS, Chan AC, Cheung TT, Chok KS, Dai WC, Poon RT, Lo CM. Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis. HPB (Oxford) 2016;18:72-8. [PMID: 26776854 DOI: 10.1016/j.hpb.2015.07.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
442 Nicolini D, Agostini A, Montalti R, Mocchegiani F, Mincarelli C, Mandolesi A, Robertson NL, Candelari R, Giovagnoni A, Vivarelli M. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. World J Gastroenterol. 2017;23:3690-3701. [PMID: 28611522 DOI: 10.3748/wjg.v23.i20.3690] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
443 Lacotte S, Oldani G, Slits F, Orci LA, Rubbia-Brandt L, Morel P, Mentha G, Toso C. Alloimmune activation promotes anti-cancer cytotoxicity after rat liver transplantation. PLoS One 2014;9:e91515. [PMID: 24651497 DOI: 10.1371/journal.pone.0091515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
444 Hafeez Bhatti AB, Qureshi AI, Tahir R, Almas T, Rana A. Liver transplantation for hepatocellular carcinoma: Improving eligibility without compromising outcomes. Ann Med Surg (Lond) 2021;68:102552. [PMID: 34295467 DOI: 10.1016/j.amsu.2021.102552] [Reference Citation Analysis]
445 Dahlqvist G, Moreno C, Starkel P, Detry O, Coubeau L, Jochmans I. Innovations in liver transplantation in 2020, position of the Belgian Liver Intestine Advisory Committee (BeLIAC). Acta Gastroenterol Belg 2021;84:347-59. [PMID: 34217187 DOI: 10.51821/84.2.347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
446 Xu DW, Wan P, Xia Q. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review. World J Gastroenterol 2016;22:3325-34. [PMID: 27022214 DOI: 10.3748/wjg.v22.i12.3325] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
447 Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, Wu LM, Chen LM, Zheng SS. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol. 2012;29:1810-1816. [PMID: 21678027 DOI: 10.1007/s12032-011-0004-z] [Cited by in Crossref: 360] [Cited by in F6Publishing: 366] [Article Influence: 36.0] [Reference Citation Analysis]
448 Lee SY, Konstantinidis IT, Eaton AA, Gönen M, Kingham TP, D'Angelica MI, Allen PJ, Fong Y, DeMatteo RP, Jarnagin WR. Predicting recurrence patterns after resection of hepatocellular cancer. HPB (Oxford) 2014;16:943-53. [PMID: 25041404 DOI: 10.1111/hpb.12311] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
449 Hernandez-Gea V, Turon F, Berzigotti A, Villanueva A. Management of small hepatocellular carcinoma in cirrhosis: focus on portal hypertension. World J Gastroenterol. 2013;19:1193-1199. [PMID: 23482437 DOI: 10.3748/wjg.v19.i8.1193] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
450 Soriano A, Varona A, Gianchandani R, Moneva ME, Arranz J, Gonzalez A, Barrera M. Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future. World J Hepatol 2016;8:58-68. [PMID: 26783421 DOI: 10.4254/wjh.v8.i1.58] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
451 Tanguturi SK, Wo JY, Zhu AX, Dawson LA, Hong TS. Radiation therapy for liver tumors: ready for inclusion in guidelines? Oncologist. 2014;19:868-879. [PMID: 25001265 DOI: 10.1634/theoncologist.2014-0097] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
452 Abbasoglu O. Liver transplantation: yesterday, today and tomorrow. World J Gastroenterol. 2008;14:3117-3122. [PMID: 18506914 DOI: 10.3748/wjg.14.3117] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
453 Li S, Zhang C, Lin LL, Wang Q, Zuo HX, Zhan AL, Luo J, Niu YM, Zhong GQ. Early-TIPS Versus Current Standard Therapy for Acute Variceal Bleeding in Cirrhosis Patients: A Systemic Review With Meta-analysis. Front Pharmacol 2020;11:603. [PMID: 32581776 DOI: 10.3389/fphar.2020.00603] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
454 Rai R. Liver transplantatation- an overview. Indian J Surg 2013;75:185-91. [PMID: 24426424 DOI: 10.1007/s12262-012-0643-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
455 Akamatsu N, Sugawara Y, Kokudo N. Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer. 2014;3:108-118. [PMID: 24945001 DOI: 10.1159/000343866] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
456 Sato M, Tateishi R, Yasunaga H, Matsui H, Fushimi K, Ikeda H, Yatomi Y, Koike K. In-hospital mortality associated with transcatheter arterial embolization for treatment of hepatocellular carcinoma in patients on hemodialysis for end stage renal disease: a matched-pair cohort study using a nationwide database. BJR Open. 2019;1:20190004. [PMID: 33178938 DOI: 10.1259/bjro.20190004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
457 Al MI, Abaalkhail FA, Bahili HA, Abdo AH, Elsiesy HA, Al MS, El Sheikh YM, Hegab BS, Kamel YM, AlGoufi TT, Hasssan HH, Burdelski MM, Al MA, Abdelfattah MR, Attallah KM, Mahmood TZ, Saleh YZ, Eldeen FZ, Broering DC. Liver transplantation at KFSHRC: achievement and challenges. Ann Saudi Med 2014;34:103-6. [PMID: 24894777 DOI: 10.5144/0256-4947.2014.103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
458 Yang PC, Ho CM, Hu RH, Ho MC, Wu YM, Lee PH. Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma. World J Hepatol 2016;8:1309-17. [PMID: 27872682 DOI: 10.4254/wjh.v8.i31.1309] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
459 Harding JJ, Khalil DN, Abou-Alfa GK. Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma? Dig Dis Sci 2019;64:918-27. [PMID: 30838478 DOI: 10.1007/s10620-019-05517-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
460 Flores A, Marrero JA. Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol 2014;8:71-6. [PMID: 24899827 DOI: 10.4137/CMO.S9926] [Cited by in Crossref: 90] [Cited by in F6Publishing: 54] [Article Influence: 12.9] [Reference Citation Analysis]
461 O'Leary C, Mahler M, Soulen MC. Curative-Intent Therapies in Localized Hepatocellular Carcinoma. Curr Treat Options Oncol 2020;21:31. [PMID: 32193784 DOI: 10.1007/s11864-020-0725-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
462 Torres HA, Kaseb A, Mahale P, Miller E, Frenette C. Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series. J Hepatocell Carcinoma 2014;1:109-14. [PMID: 27508180 DOI: 10.2147/JHC.S60867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
463 Sun P, Dong X, Cheng X, Hu Q, Zheng Q. Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. PLoS One. 2014;9:e102761. [PMID: 25058587 DOI: 10.1371/journal.pone.0102761] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
464 Takayama K, Akita N, Mimura N, Akahira R, Taniguchi Y, Ikeda M, Sakurai F, Ohara O, Morio T, Sekiguchi K, Mizuguchi H. Generation of safe and therapeutically effective human induced pluripotent stem cell-derived hepatocyte-like cells for regenerative medicine. Hepatol Commun. 2017;1:1058-1069. [PMID: 29404442 DOI: 10.1002/hep4.1111] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
465 Sogawa H, Shrager B, Jibara G, Tabrizian P, Roayaie S, Schwartz M. Resection or transplant-listing for solitary hepatitis C-associated hepatocellular carcinoma: an intention-to-treat analysis. HPB (Oxford). 2013;15:134-141. [PMID: 23036070 DOI: 10.1111/j.1477-2574.2012.00548.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
466 Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19. [PMID: 22904613 DOI: 10.2147/BTT.S23907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 24] [Article Influence: 0.6] [Reference Citation Analysis]
467 Heinrich S, Sprinzl M, Schmidtmann I, Heil E, Koch S, Czauderna C, Heinrich B, Philippe P Diggs L, Wörns MA, Kloeckner R, Galle PR, Marquardt JU, Weinmann A. Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. United European Gastroenterol J 2020;8:444-52. [PMID: 32213028 DOI: 10.1177/2050640620904524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
468 Nakajima Y, Takagi H, Sohara N, Sato K, Kakizaki S, Nomoto K, Suzuki H, Suehiro T, Shimura T, Asao T, Kuwano H, Mori M, Nishikura K. Living-related liver transplantation for multiple liver metastases from rectal carcinoid tumor: a case report. World J Gastroenterol 2006;12:1805-9. [PMID: 16586560 DOI: 10.3748/wjg.v12.i11.1805] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
469 Meischl T, Rasoul-Rockenschaub S, Győri G, Scheiner B, Trauner M, Soliman T, Berlakovich G, Pinter M. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma. United European Gastroenterol J 2021;9:209-19. [PMID: 32741316 DOI: 10.1177/2050640620948665] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
470 Geissler EK, Schnitzbauer AA, Zülke C, Lamby PE, Proneth A, Duvoux C, Burra P, Jauch KW, Rentsch M, Ganten TM, Schmidt J, Settmacher U, Heise M, Rossi G, Cillo U, Kneteman N, Adam R, van Hoek B, Bachellier P, Wolf P, Rostaing L, Bechstein WO, Rizell M, Powell J, Hidalgo E, Gugenheim J, Wolters H, Brockmann J, Roy A, Mutzbauer I, Schlitt A, Beckebaum S, Graeb C, Nadalin S, Valente U, Turrión VS, Jamieson N, Scholz T, Colledan M, Fändrich F, Becker T, Söderdahl G, Chazouillères O, Mäkisalo H, Pageaux GP, Steininger R, Soliman T, de Jong KP, Pirenne J, Margreiter R, Pratschke J, Pinna AD, Hauss J, Schreiber S, Strasser S, Klempnauer J, Troisi RI, Bhoori S, Lerut J, Bilbao I, Klein CG, Königsrainer A, Mirza DF, Otto G, Mazzaferro V, Neuhaus P, Schlitt HJ. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation 2016;100:116-25. [PMID: 26555945 DOI: 10.1097/TP.0000000000000965] [Cited by in Crossref: 189] [Cited by in F6Publishing: 77] [Article Influence: 37.8] [Reference Citation Analysis]
471 Bodzin AS. Hepatocellular carcinoma (HCC) recurrence and what to do when it happens. Hepatobiliary Surg Nutr 2016;5:503-5. [PMID: 28124008 DOI: 10.21037/hbsn.2016.11.06] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
472 Khungar V, Goldberg DS. Liver Transplantation for Cholestatic Liver Diseases in Adults. Clin Liver Dis. 2016;20:191-203. [PMID: 26593299 DOI: 10.1016/j.cld.2015.08.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
473 Teng F, Han QC, Ding GS, Ni ZJ, Fu H, Guo WY, Shi XM, Gao XG, Ma J, Fu ZR. Validation of a criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation. Sci Rep 2015;5:11733. [PMID: 26096817 DOI: 10.1038/srep11733] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
474 Tholey DM, Hornung B, Enestvedt CK, Chen Y, Naugler WS, Farsad K, Nabavizadeh N, Schlansky B, Ahn J, Jou JH. Close observation versus upfront treatment in hepatocellular carcinoma: are the exception points worth the risk? BMJ Open Gastroenterol 2017;4:e000157. [PMID: 28944072 DOI: 10.1136/bmjgast-2017-000157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
475 Macdonald B, Sewell JL, Harper AM, Roberts JP, Yao FY. Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5. Clin Transplant. 2015;29:506-512. [PMID: 25777321 DOI: 10.1111/ctr.12542] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
476 Fisher RA. Living donor liver transplantation: eliminating the wait for death in end-stage liver disease? Nat Rev Gastroenterol Hepatol. 2017;14:373-382. [PMID: 28196987 DOI: 10.1038/nrgastro.2017.2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
477 Yokomori H, Oda M, Kaneko F, Kawachi S, Tanabe M, Yoshimura K, Kitagawa Y, Hibi T. Lymphatic marker podoplanin/D2-40 in human advanced cirrhotic liver--re-evaluations of microlymphatic abnormalities. BMC Gastroenterol. 2010;10:131. [PMID: 21059220 DOI: 10.1186/1471-230x-10-131] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
478 Dipasquale A, Marinello A, Santoro A. A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario. J Hepatocell Carcinoma 2021;8:241-51. [PMID: 33884259 DOI: 10.2147/JHC.S270532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
479 Zhu SL, Ke Y, Peng YC, Ma L, Li H, Li LQ, Zhong JH. Comparison of long-term survival of patients with solitary large hepatocellular carcinoma of BCLC stage A after liver resection or transarterial chemoembolization: a propensity score analysis. PLoS One. 2014;9:e115834. [PMID: 25541684 DOI: 10.1371/journal.pone.0115834.ecollection] [Reference Citation Analysis]
480 Graziadei I, Zoller H, Fickert P, Schneeberger S, Finkenstedt A, Peck-Radosavljevic M, Müller H, Kohl C, Sperner-Unterweger B, Eschertzhuber S, Hofer H, Öfner D, Tilg H, Vogel W, Trauner M, Berlakovich G. Indications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX). Wien Klin Wochenschr 2016;128:679-90. [PMID: 27590261 DOI: 10.1007/s00508-016-1046-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
481 Niendorf E, Spilseth B, Wang X, Taylor A. Contrast Enhanced MRI in the Diagnosis of HCC. Diagnostics (Basel). 2015;5:383-398. [PMID: 26854161 DOI: 10.3390/diagnostics5030383] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
482 Lacaze L, Scotté M. Surgical treatment of intra hepatic recurrence of hepatocellular carcinoma. World J Hepatol 2015;7:1755-60. [PMID: 26167248 DOI: 10.4254/wjh.v7.i13.1755] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
483 Maithel SK, Kneuertz PJ, Kooby DA, Scoggins CR, Weber SM, Martin RC, McMasters KM, Cho CS, Winslow ER, Wood WC. Importance of low preoperative platelet count in selecting patients for resection of hepatocellular carcinoma: a multi-institutional analysis. J Am Coll Surg. 2011;212:638-648; discussion 648-650. [PMID: 21463803 DOI: 10.1016/j.jamollsurg.2011.01.004] [Reference Citation Analysis]
484 Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, Peng ZH. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol. 2012;138:153-161. [PMID: 22071603 DOI: 10.1007/s00432-011-] [Reference Citation Analysis]
485 Karatoprak S, Kutlu R, Yılmaz S. Role of percutaneous radiological treatment in biliary complications associated with adult left lobe living donor liver transplantation: a single-center experience. Diagn Interv Radiol 2021;27:546-52. [PMID: 33599206 DOI: 10.5152/dir.2021.20523] [Reference Citation Analysis]
486 Weis S, Franke A, Berg T, Mössner J, Fleig WE, Schoppmeyer K. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev 2015;1:CD006745. [PMID: 25620061 DOI: 10.1002/14651858.CD006745.pub3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
487 Chen S, Ma W, Cao F, Shen L, Qi H, Xie L, Wu Y, Fan W. Hepatocellular Carcinoma Within the Milan Criteria: A Novel Inflammation-Based Nomogram System to Assess the Outcomes of Ablation. Front Oncol 2020;10:1764. [PMID: 33042823 DOI: 10.3389/fonc.2020.01764] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
488 Habibollahi P, Sheth RA, Cressman ENK. Histological Correlation for Radiofrequency and Microwave Ablation in the Local Control of Hepatocellular Carcinoma (HCC) before Liver Transplantation: A Comprehensive Review.Cancers (Basel). 2020;13. [PMID: 33396289 DOI: 10.3390/cancers13010104] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
489 He JJ, Shang L, Yu QW, Jiao N, Qiu S, Zhu WX, Wu DF, Tian YE, Zhang Q. High expression of protein phosphatase 2 regulatory subunit B'' alpha predicts poor outcome in hepatocellular carcinoma patients after liver transplantation. World J Gastrointest Oncol 2021;13:716-31. [PMID: 34322200 DOI: 10.4251/wjgo.v13.i7.716] [Reference Citation Analysis]
490 Romano F, Chiarelli M, Garancini M, Scotti M, Zago M, Cioffi G, De Simone M, Cioffi U. Rethinking the Barcelona clinic liver cancer guidelines: Intermediate stage and Child-Pugh B patients are suitable for surgery? World J Gastroenterol 2021;27:2784-94. [PMID: 34135554 DOI: 10.3748/wjg.v27.i21.2784] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
491 Azer SA, Azer S. Bibliometric analysis of the top-cited gastroenterology and hepatology articles. BMJ Open 2016;6:e009889. [PMID: 26857105 DOI: 10.1136/bmjopen-2015-009889] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
492 Roccarina D, Majumdar A, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis. Cochrane Database Syst Rev. 2017;3:CD011649. [PMID: 28281295 DOI: 10.1002/14651858.cd011649.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
493 Arif-Tiwari H, Kalb B, Chundru S, Sharma P, Costello J, Guessner RW, Martin DR. MRI of hepatocellular carcinoma: an update of current practices. Diagn Interv Radiol. 2014;20:209-221. [PMID: 24808419 DOI: 10.5152/dir.2014.13370] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
494 Cárdenes HR. Role of stereotactic body radiotherapy in the management of primary hepatocellular carcinoma. Rationale, technique and results. Clin Transl Oncol 2009;11:276-83. [DOI: 10.1007/s12094-009-0355-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
495 Chan MV, McDonald SJ, Ong YY, Mastrocostas K, Ho E, Huo YR, Santhakumar C, Lee AU, Yang J. HCC screening: assessment of an abbreviated non-contrast MRI protocol. Eur Radiol Exp 2019;3:49. [PMID: 31853685 DOI: 10.1186/s41747-019-0126-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
496 Cabrera R, Dhanasekaran R, Caridi J, Clark V, Morelli G, Soldevila-Pico C, Magglioca J, Nelson D, Firpi RJ. Impact of transarterial therapy in hepatitis C-related hepatocellular carcinoma on long-term outcomes after liver transplantation. Am J Clin Oncol 2012;35:345-50. [PMID: 21552101 DOI: 10.1097/COC.0b013e31821631f6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
497 Min AL, Choi JY, Woo HY, Kim JD, Kwon JH, Bae SH, Yoon SK, Shin SH, Chung YJ, Jung CK. High expression of Snail mRNA in blood from hepatocellular carcinoma patients with extra-hepatic metastasis. Clin Exp Metastasis. 2009;26:759-767. [PMID: 19533388 DOI: 10.1007/s10585-009-9275-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
498 Kim DH, Choi SH, Shim JH, Kim SY, Lee SS, Byun JH, Choi JI. Meta-Analysis of the Accuracy of Abbreviated Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance: Non-Contrast versus Hepatobiliary Phase-Abbreviated Magnetic Resonance Imaging. Cancers (Basel) 2021;13:2975. [PMID: 34198589 DOI: 10.3390/cancers13122975] [Reference Citation Analysis]
499 Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol. 2010;17:1226-1233. [PMID: 20405327 DOI: 10.1245/s10434-010-0978-3.] [Reference Citation Analysis]
500 Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol. 2015;7:1632-1651. [PMID: 26140083 DOI: 10.4254/wjh.v7.i12.1632] [Cited by in Crossref: 113] [Cited by in F6Publishing: 97] [Article Influence: 18.8] [Reference Citation Analysis]
501 Kotewall CN, Cheung TT. Optimizing hepatectomy for hepatocellular carcinoma in Asia-patient selection and special considerations. Transl Gastroenterol Hepatol 2018;3:75. [PMID: 30505962 DOI: 10.21037/tgh.2018.09.09] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
502 Geh D, Manas DM, Reeves HL. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr 2021;10:59-75. [PMID: 33575290 DOI: 10.21037/hbsn.2019.08.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
503 Brusset B, Dumortier J, Cherqui D, Pageaux GP, Boleslawski E, Chapron L, Quesada JL, Radenne S, Samuel D, Navarro F, Dharancy S, Decaens T. Liver Transplantation for Hepatocellular Carcinoma: A Real-Life Comparison of Milan Criteria and AFP Model. Cancers (Basel) 2021;13:2480. [PMID: 34069594 DOI: 10.3390/cancers13102480] [Reference Citation Analysis]
504 Sharma P, Saini SD, Kuhn LB, Rubenstein JH, Pardi DS, Marrero JA, Schoenfeld PS. Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists. Dig Dis Sci. 2011;56:569-577. [PMID: 20978844 DOI: 10.1007/s10620-010-1453-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
505 Tran SA, Le A, Zhao C, Hoang J, Yasukawa LA, Weber S, Henry L, Nguyen MH. Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis. BMJ Open Gastroenterol 2018;5:e000192. [PMID: 29607053 DOI: 10.1136/bmjgast-2017-000192] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
506 Toshima T, Shirabe K, Ikegami T, Yoshizumi T, Kuno A, Togayachi A, Gotoh M, Narimatsu H, Korenaga M, Mizokami M, Nishie A, Aishima S, Maehara Y. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis. J Gastroenterol. 2015;50:76-84. [PMID: 24603981 DOI: 10.1007/s00535-014-0946-y] [Cited by in Crossref: 113] [Cited by in F6Publishing: 104] [Article Influence: 16.1] [Reference Citation Analysis]
507 Shen JY, Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, Xu MQ, Nazar Highness T. Liver transplantation versus surgical resection for HCC meeting the Milan criteria: A propensity score analysis. Medicine (Baltimore) 2016;95:e5756. [PMID: 28033289 DOI: 10.1097/MD.0000000000005756] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
508 Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20:945-951. [PMID: 24797281 DOI: 10.1002/lt.23904] [Cited by in Crossref: 145] [Cited by in F6Publishing: 128] [Article Influence: 20.7] [Reference Citation Analysis]
509 Kabbach G, Assi HA, Bolotin G, Schuster M, Lee HJ, Tadros M. Hepatobiliary Tumors: Update on Diagnosis and Management. J Clin Transl Hepatol 2015;3:169-81. [PMID: 26623263 DOI: 10.14218/JCTH.2015.00012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
510 Dakhoul L, Gawrieh S, Jones KR, Ghabril M, McShane C, Orman E, Vilar-Gomez E, Chalasani N, Nephew L. Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma Are Not Explained by Differences in Comorbidities, Liver Disease Severity, or Tumor Burden. Hepatol Commun 2019;3:52-62. [PMID: 30619994 DOI: 10.1002/hep4.1277] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
511 Mahmud N. Selection for Liver Transplantation: Indications and Evaluation. Curr Hepatol Rep 2020;:1-10. [PMID: 32837824 DOI: 10.1007/s11901-020-00527-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
512 Manzini G, Henne-Bruns D, Porzsolt F, Kremer M. Is there a standard for surgical therapy of hepatocellular carcinoma in healthy and cirrhotic liver? BMJ Open Gastroenterol. 2017;4:e000129. [PMID: 28405349 DOI: 10.1136/bmjgast-2016-000129] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
513 Li J, Liang L, Liu Y, Luo Y, Liang X, Luo D, Feng Z, Dang Y, Yang L, Chen G. Clinicopathological significance of STAT4 in hepatocellular carcinoma and its effect on cell growth and apoptosis. Onco Targets Ther 2016;9:1721-34. [PMID: 27051307 DOI: 10.2147/OTT.S100040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
514 Na GH, Kim DG, Han JH, Kim EY, Lee SH, Hong TH, You YK. Inflammatory markers as selection criteria of hepatocellular carcinoma in living-donor liver transplantation. World J Gastroenterol. 2014;20:6594-6601. [PMID: 24914382 DOI: 10.3748/wjg.v20.i21.6594] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
515 Eisenbrey JR, Forsberg F, Wessner CE, Delaney LJ, Bradigan K, Gummadi S, Tantawi M, Lyshchik A, O'Kane P, Liu JB, Intenzo C, Civan J, Maley W, Keith SW, Anton K, Tan A, Smolock A, Shamimi-Noori S, Shaw CM. US-triggered Microbubble Destruction for Augmenting Hepatocellular Carcinoma Response to Transarterial Radioembolization: A Randomized Pilot Clinical Trial. Radiology 2021;298:450-7. [PMID: 33320067 DOI: 10.1148/radiol.2020202321] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
516 Baldassarre M, Domenicali M, Naldi M, Laggetta M, Giannone FA, Biselli M, Patrono D, Bertucci C, Bernardi M, Caraceni P. Albumin Homodimers in Patients with Cirrhosis: Clinical and Prognostic Relevance of a Novel Identified Structural Alteration of the Molecule. Sci Rep 2016;6:35987. [PMID: 27782157 DOI: 10.1038/srep35987] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
517 Tsai YF, Liu FC, Chen CY, Lin JR, Yu HP. Effect of Mycophenolate Mofetil Therapy on Recurrence of Hepatocellular Carcinoma after Liver Transplantation: A Population-Based Cohort Study. J Clin Med 2021;10:1558. [PMID: 33917215 DOI: 10.3390/jcm10081558] [Reference Citation Analysis]
518 Belghiti J, Fuks D. Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer. 2012;1:71-82. [PMID: 24159575 DOI: 10.1159/00034240] [Reference Citation Analysis]
519 Wang HL, Mo DC, Zhong JH, Ma L, Wu FX, Xiang BD, Li LQ. Systematic review of treatment strategy for recurrent hepatocellular carcinoma: Salvage liver transplantation or curative locoregional therapy. Medicine (Baltimore) 2019;98:e14498. [PMID: 30813151 DOI: 10.1097/MD.0000000000014498] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
520 Bell R, Pandanaboyana S, Lodge JPA, Prasad KR, Jones R, Hidalgo E. Primary liver resection for patients with cirrhosis and hepatocellular carcinoma: the role of surgery in BCLC early (A) and intermediate stages (B). Langenbecks Arch Surg. 2017;402:575-583. [PMID: 27456677 DOI: 10.1007/s00423-016-1475-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
521 Dorcaratto D, Udupa V, Hogan NM, Brophy DP, McCann JW, Maguire D, Geoghegan J, Cantwell CP, Hoti E. Does neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization improve survival in patients undergoing liver transplant for hepatocellular carcinoma? Diagn Interv Radiol 2017;23:441-7. [PMID: 29063856 DOI: 10.5152/dir.2017.17106] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
522 Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, Zahlten-Hinguranage A, Schirrmacher P, Schmidt J, Büchler MW. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer. 2008;8:349. [PMID: 19036146 DOI: 10.1186/1471-2407-8-3491471-2407-8-349] [Reference Citation Analysis]
523 Zhang DZ, Wei XD, Wang XP. Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma. World J Gastroenterol 2015;21:4635-43. [PMID: 25914473 DOI: 10.3748/wjg.v21.i15.4635] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
524 Kishi Y, Shimada K, Nara S, Esaki M, Kosuge T. Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma. World J Hepatol 2014;6:836-43. [PMID: 25544870 DOI: 10.4254/wjh.v6.i12.836] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
525 Huang G, Jiang H, Lin Y, Wu Y, Cai W, Shi B, Luo Y, Jian Z, Zhou X. Prognostic value of plasma fibrinogen in hepatocellular carcinoma: a meta-analysis. Cancer Manag Res 2018;10:5027-41. [PMID: 30464603 DOI: 10.2147/CMAR.S175780] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
526 Kim J, Zimmerman MA, Hong JC. Liver transplantation in the treatment of unresectable hepatic metastasis from neuroendocrine tumors. J Gastrointest Oncol. 2020;11:601-608. [PMID: 32655939 DOI: 10.21037/jgo.2019.11.03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
527 Goossens N, Singal AG, King LY, Andersson KL, Fuchs BC, Besa C, Taouli B, Chung RT, Hoshida Y. Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. Clin Transl Gastroenterol 2017;8:e101. [PMID: 28640287 DOI: 10.1038/ctg.2017.26] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 16.0] [Reference Citation Analysis]
528 Ulahannan SV, Duffy AG, McNeel TS, Kish JK, Dickie LA, Rahma OE, McGlynn KA, Greten TF, Altekruse SF. Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology. 2014;60:1637-1644. [PMID: 24996116 DOI: 10.1002/hep.27288] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 8.4] [Reference Citation Analysis]
529 Abdo AA, Hassanain M, AlJumah A, Al Olayan A, Sanai FM, Alsuhaibani HA, Abdulkareem H, Abdallah K, AlMuaikeel M, Al Saghier M, Babatin M, Kabbani M, Bazarbashi S, Metrakos P, Bruix J; Saudi Association for the Study of Liver Diseases and Transplantation., Saudi Oncology Society. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 2012;32:174-99. [PMID: 22366832 DOI: 10.5144/0256-4947.2012.174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
530 Grazi GL, Ercolani G, Pierangeli F, Del Gaudio M, Cescon M, Cavallari A, Mazziotti A. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg 2001;234:71-8. [PMID: 11420485 DOI: 10.1097/00000658-200107000-00011] [Cited by in Crossref: 248] [Cited by in F6Publishing: 227] [Article Influence: 12.4] [Reference Citation Analysis]
531 Alim A, Erdogan Y, Dayangac M, Yuzer Y, Tokat Y, Oezcelik A. Living Donor Liver Transplantation: The Optimal Curative Treatment for Hepatocellular Carcinoma Even Beyond Milan Criteria. Cancer Control 2021;28:10732748211011960. [PMID: 33926242 DOI: 10.1177/10732748211011960] [Reference Citation Analysis]
532 Kyrochristos ID, Glantzounis GK, Ziogas DE, Gizas I, Schizas D, Lykoudis EG, Felekouras E, Machairas A, Katsios C, Liakakos T, Cho WC, Roukos DH. From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. Int J Mol Sci 2017;18:E180. [PMID: 28106782 DOI: 10.3390/ijms18010180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
533 Aghemo A, Colombo M. Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol 2013;35:111-20. [DOI: 10.1007/s00281-012-0330-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
534 Morise Z. Developments and perspectives of laparoscopic liver resection in the treatment of hepatocellular carcinoma. Surg Today 2019;49:649-55. [PMID: 30649611 DOI: 10.1007/s00595-019-1765-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
535 Ofosu A, Gurakar A. Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: A Review and 2014 Update. Euroasian J Hepatogastroenterol 2015;5:19-25. [PMID: 29201680 DOI: 10.5005/jp-journals-10018-1123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
536 Memon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R. Radioembolization for primary and metastatic liver cancer. Semin Radiat Oncol. 2011;21:294-302. [PMID: 21939859 DOI: 10.1016/j.semradonc.2011.05.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
537 Attia F, Fathy S, Anani M, Hassan A, Attia F, Ibrahim G, Elazab M. Human equilibrative nucleoside transporter-1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma. J Clin Lab Anal 2020;34:e23457. [PMID: 32671914 DOI: 10.1002/jcla.23457] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
538 Ekpanyapong S, Philips N, Loza BL, Abt P, Furth EE, Tondon R, Khungar V, Olthoff K, Shaked A, Hoteit MA, Reddy KR. Predictors, Presentation, and Treatment Outcomes of Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Large Single Center Experience. J Clin Exp Hepatol 2020;10:304-15. [PMID: 32655233 DOI: 10.1016/j.jceh.2019.11.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
539 Villa E, Ferretti I, Grottola A, Buttafoco P, Buono MG, Giannini F, Manno M, Bertani H, Dugani A, Manenti F. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer. 2001;84:881-885. [PMID: 11286465 DOI: 10.1054/bjoc.2000.1534] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 3.3] [Reference Citation Analysis]
540 Maithel SK, Kneuertz PJ, Kooby DA, Scoggins CR, Weber SM, Martin RC 2nd, McMasters KM, Cho CS, Winslow ER, Wood WC, Staley CA 3rd. Importance of low preoperative platelet count in selecting patients for resection of hepatocellular carcinoma: a multi-institutional analysis. J Am Coll Surg. 2011;212:638-648; discussion 648-650. [PMID: 21463803 DOI: 10.1016/j.jamcollsurg.2011.01.004] [Cited by in Crossref: 82] [Cited by in F6Publishing: 68] [Article Influence: 8.2] [Reference Citation Analysis]
541 Liu Y, Li H, Ye N, Luo CJ, Hu YY, Wu H, Gong JP. Non-Cirrhotic Liver is Associated with Poor Prognosis of Hepatocellular Carcinoma: A Literature Review. Med Sci Monit 2019;25:6615-23. [PMID: 31479436 DOI: 10.12659/MSM.915722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
542 Detry O, Govaerts L, Deroover A, Vandermeulen M, Meurisse N, Malenga S, Bletard N, Mbendi C, Lamproye A, Honoré P. Prognostic value of (18)F-FDG PET/CT in liver transplantation for hepatocarcinoma. World J Gastroenterol. 2015;21:3049-3054. [PMID: 25780305 DOI: 10.3748/wjg.v21.i10.3049] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
543 Abbadessa G, Rimassa L, Pressiani T, Carrillo-Infante C, Cucchi E, Santoro A. Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib. World J Gastroenterol. 2011;17:2450-2453. [PMID: 21633647 DOI: 10.3748/wjg.v17.i19.2450] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
544 Li J, Yan LN, Yang J, Chen ZY, Li B, Zeng Y, Wen TF, Zhao JC, Wang WT, Yang JY. Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients. World J Gastroenterol. 2009;15:4170-4176. [PMID: 19725152 DOI: 10.3748/wjg.15.4170] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
545 Morise Z, Kawabe N, Tomishige H, Nagata H, Kawase J, Arakawa S, Yoshida R, Isetani M. Recent advances in the surgical treatment of hepatocellular carcinoma. World J Gastroenterol. 2014;20:14381-14392. [PMID: 25339825 DOI: 10.3748/wjg.v20.i39.14381] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
546 Jakobs TF, Hoffmann RT, Tatsch K, Trumm C, Reiser MF, Helmberger TK. [Developments and perspectives in radioablative techniques]. Radiologe. 2007;47:1083-1088. [PMID: 17943265 DOI: 10.1007/s00117-007-1572-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
547 Smith MT, Ray CE. The treatment of primary and metastatic hepatic neoplasms using percutaneous cryotherapy. Semin Intervent Radiol. 2006;23:39-46. [PMID: 21326719 DOI: 10.1055/s-2006-939840] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
548 Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, Denninger MH, Sauvanet A, Valla D, Durand F. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005;54:691-697. [PMID: 15831918 DOI: 10.1136/gut.2004.042796]] [Reference Citation Analysis]
549 Grąt M, Stypułkowski J, Patkowski W, Wronka KM, Bik E, Krasnodębski M, Masior Ł, Lewandowski Z, Wasilewicz M, Grąt K, Krawczyk M, Zieniewicz K. Challenging the principle of utility as a barrier for wider use of liver transplantation for hepatocellular cancer. Ann Surg Oncol 2017;24:3188-95. [PMID: 28695391 DOI: 10.1245/s10434-017-5989-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
550 Goldberg D, Mantero A, Newcomb C, Delgado C, Forde KA, Kaplan DE, John B, Nuchovich N, Dominguez B, Emanuel E, Reese PP. Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score. J Hepatol. 2021;74:1398-1406. [PMID: 33453328 DOI: 10.1016/j.jhep.2020.12.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
551 Trivedi PJ, Cullen S. Autoimmune hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Dig Dis Sci 2011;56:276-8. [PMID: 21127980 DOI: 10.1007/s10620-010-1476-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
552 Suh KS, Lee HW. Liver transplantation for advanced hepatocellular carcinoma: how far can we go? Hepat Oncol 2015;2:19-28. [PMID: 30190984 DOI: 10.2217/hep.14.34] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
553 Yim HJ, Suh SJ, Um SH. Current management of hepatocellular carcinoma: an Eastern perspective. World J Gastroenterol. 2015;21:3826-3842. [PMID: 25852267 DOI: 10.3748/wjg.v21.i13.3826] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
554 Chao JS, Zhao SL, Ou-Yang SW, Qian YB, Liu AQ, Tang HM, Zhong L, Peng ZH, Xu JM, Sun HC. Post-transplant infection improves outcome of hepatocellular carcinoma patients after orthotopic liver transplantation. World J Gastroenterol 2019;25:5630-40. [PMID: 31602163 DOI: 10.3748/wjg.v25.i37.5630] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
555 Ippolito D, Capraro C, Casiraghi A, Cestari C, Sironi S. Quantitative assessment of tumour associated neovascularisation in patients with liver cirrhosis and hepatocellular carcinoma: role of dynamic-CT perfusion imaging. Eur Radiol. 2012;22:803-811. [PMID: 22086560 DOI: 10.1007/s00330-011-2307-z] [Cited by in Crossref: 60] [Cited by in F6Publishing: 44] [Article Influence: 6.0] [Reference Citation Analysis]
556 Renne SL, Sarcognato S, Sacchi D, Guido M, Roncalli M, Terracciano L, Di Tommaso L. Hepatocellular carcinoma: a clinical and pathological overview. Pathologica 2021;113:203-17. [PMID: 34294938 DOI: 10.32074/1591-951X-295] [Reference Citation Analysis]
557 Schlachterman A, Craft WW, Hilgenfeldt E, Mitra A, Cabrera R. Current and future treatments for hepatocellular carcinoma. World J Gastroenterol. 2015;21:8478-8491. [PMID: 26229392 DOI: 10.3748/wjg.v21.i28.8478] [Cited by in CrossRef: 94] [Cited by in F6Publishing: 82] [Article Influence: 18.8] [Reference Citation Analysis]
558 Esagian SM, Kakos CD, Giorgakis E, Burdine L, Barreto JC, Mavros MN. Adjuvant Transarterial Chemoembolization Following Curative-Intent Hepatectomy Versus Hepatectomy Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cancers (Basel) 2021;13:2984. [PMID: 34203692 DOI: 10.3390/cancers13122984] [Reference Citation Analysis]
559 Youness ER, El Nemr M, Oraby FS, Ahmed NM, Moghni MA, Aly HF, Ahmed HH. Evaluation of Apoptotic Marker Bcl2, CD4+, Human Hepatocyte Growth Factor and Metalloproteinase-9 as Tumor Markers for Patients with Hepatocellular Carcinoma. Indian J Clin Biochem 2014;29:351-6. [PMID: 24966485 DOI: 10.1007/s12291-013-0381-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
560 Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, Rapaccini GL, Gasbarrini G. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005;54:411-8. [PMID: 15710992 DOI: 10.1136/gut.2004.048124] [Cited by in Crossref: 173] [Cited by in F6Publishing: 157] [Article Influence: 10.8] [Reference Citation Analysis]
561 Esfeh JM, Hajifathalian K, Ansari-Gilani K. Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard. Clin Mol Hepatol. 2020;26:54-59. [PMID: 31726817 DOI: 10.3350/cmh.2019.0039] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
562 Zhou YM, Wen YH, Kang XY, Qian HH, Yang JM, Yin ZF. Troglitazone, a peroxisome proliferator-activated receptor gamma ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells. World J Gastroenterol 2008;14:2168-73. [PMID: 18407589 DOI: 10.3748/wjg.14.2168] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
563 Zhou J, Huang Z, Chen Z, Xu F, Tong R, Zheng S. Impact of donor age on liver transplant outcomes in patients with hepatocellular carcinoma: analysis of the SRTR database. BMC Gastroenterol 2021;21:195. [PMID: 33931011 DOI: 10.1186/s12876-021-01786-6] [Reference Citation Analysis]
564 Xia W, Ke Q, Guo H, Wang W, Zhang M, Shen Y, Wu J, Xu X, Yan S, Yu J, Zhang M, Zheng S. Expansion of the Milan criteria without any sacrifice: combination of the Hangzhou criteria with the pre-transplant platelet-to-lymphocyte ratio. BMC Cancer. 2017;17:14. [PMID: 28056901 DOI: 10.1186/s12885-016-3028-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
565 Grąt M, Kornasiewicz O, Lewandowski Z, Hołówko W, Grąt K, Kobryń K, Patkowski W, Zieniewicz K, Krawczyk M. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg 2014;38:2698-707. [PMID: 24858191 DOI: 10.1007/s00268-014-2647-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
566 Cescon M, Bertuzzo VR, Ercolani G, Ravaioli M, Odaldi F, Pinna AD. Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis. World J Gastroenterol. 2013;19:9174-9182. [PMID: 24409045 DOI: 10.3748/wjg.v19.i48.9174] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
567 Wu TH, Wang YC, Cheng CH, Lee CF, Wu TJ, Chou HS, Chan KM, Lee WC. Outcomes associated with the intention of loco-regional therapy prior to living donor liver transplantation for hepatocellular carcinoma. World J Gastrointest Surg 2020;12:17-27. [PMID: 31984121 DOI: 10.4240/wjgs.v12.i1.17] [Reference Citation Analysis]
568 Purcell Y, Copin P, Paulatto L, Pommier R, Vilgrain V, Ronot M. Hepatocellular carcinoma surveillance: Eastern and Western perspectives. Ultrasonography 2019;38:191-9. [PMID: 30690962 DOI: 10.14366/usg.18043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
569 Cormier J, Thomas K, Chari R, Pinson C. Management of Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery 2006;10:761-80. [DOI: 10.1016/j.gassur.2005.10.006] [Cited by in Crossref: 60] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]
570 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
571 Kakodkar R, Soin AS. Liver Transplantation for HCC: A Review. Indian J Surg. 2012;74:100-117. [PMID: 23372314 DOI: 10.1007/s12262-011-0387-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
572 Bento de Sousa JH, Calil IL, Tustumi F, da Cunha Khalil D, Felga GEG, de Arruda Pecora RA, de Almeida MD. Comparison between Milan and UCSF criteria for liver transplantation in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Transl Gastroenterol Hepatol. 2021;6:11. [PMID: 33409405 DOI: 10.21037/tgh.2020.01.06] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
573 Ladd LM, Tirkes T, Tann M, Agarwal DM, Johnson MS, Tahir B, Sandrasegaran K. Comparison of hepatic MDCT, MRI, and DSA to explant pathology for the detection and treatment planning of hepatocellular carcinoma. Clin Mol Hepatol 2016;22:450-7. [PMID: 27987537 DOI: 10.3350/cmh.2016.0036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
574 Sacco R, Bargellini I, Gianluigi G, Bertini M, Bozzi E, Altomare E, Battaglia V, Romano A, Bertoni M, Capria A. Complete response for advanced liver cancer during sorafenib therapy: case report. BMC Gastroenterol. 2011;11:4. [PMID: 21241463 DOI: 10.1186/1471-230x-11-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
575 Castellanos Fernández MI, Cepeda Mullo ME, la Rosa Hernández D, Vega Sánchez H, González Fabian L, Gish RG, Torres González AL, Dorta Guridi Z. Autoimmune Hepatitis in Cuban Patients: A Retrospective Analysis of Clinical and Histological Profiles, Treatments, and Outcomes. Curr Ther Res Clin Exp 2020;93:100594. [PMID: 32922567 DOI: 10.1016/j.curtheres.2020.100594] [Reference Citation Analysis]
576 Teng F, Wang GH, Tao YF, Guo WY, Wang ZX, Ding GS, Shi XM, Fu ZR. Criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation. World J Gastroenterol 2014;20:10900-7. [PMID: 25152592 DOI: 10.3748/wjg.v20.i31.10900] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
577 Güney İB. HCC Locoregional Therapies: Yttrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT). J Gastrointest Cancer 2017;48:276-80. [PMID: 28634672 DOI: 10.1007/s12029-017-9973-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
578 Belghiti J, Fuks D. Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer. 2012;1:71-82. [PMID: 24159575 DOI: 10.1159/000342403] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 7.7] [Reference Citation Analysis]
579 Wang P, Li H, Shi B, Que W, Wang C, Fan J, Peng Z, Zhong L. Prognostic factors in patients with recurrent hepatocellular carcinoma treated with salvage liver transplantation: a single-center study. Oncotarget 2016;7:35071-83. [PMID: 27145461 DOI: 10.18632/oncotarget.9040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
580 Jiang Y, Tang H, Wang Z, Sun Y, Meng W, Wang G, Li H, Yi S, Wang G, Yang Y, Chen G. Two Nomograms to Select Hepatocellular Carcinoma Patients with Macroscopic Vascular Invasion for Hepatic Resection. J Cancer 2018;9:3287-94. [PMID: 30271488 DOI: 10.7150/jca.25899] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
581 Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Fox R, Yeo W, Mo F, Lai P, Chan SL, Tada T, Toyoda H, Kumada T. Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. Br J Cancer. 2017;116:441-447. [PMID: 28081537 DOI: 10.1038/bjc.2016.422] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
582 Bartlett A, Heaton N. Hepatocellular carcinoma: defining the place of surgery in an era of organ shortage. World J Gastroenterol. 2008;14:4445-4453. [PMID: 18680222 DOI: 10.3748/wjg.14.4445] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
583 Uchino K, Obi S, Tateishi R, Sato S, Kanda M, Sato T, Arano T, Enooku K, Goto E, Masuzaki R. Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. J Gastroenterol. 2012;47:1152-1159. [PMID: 22438097 DOI: 10.1007/s00535-012-0574-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
584 Strassburg CP. HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations? Visc Med 2016;32:263-71. [PMID: 27722163 DOI: 10.1159/000446385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
585 El-Zayadi AR, Badran HM, Shawky S, Emara S, El-Bareedy A, Sobhi M. Effect of surveillance for hepatocellular carcinoma on tumor staging and treatment decisions in Egyptian patients. Hepatol Int 2010;4:500-6. [PMID: 20827407 DOI: 10.1007/s12072-010-9170-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
586 Guo X, Xu Y, Wang X, Lin F, Wu H, Duan J, Xiong Y, Han X, Baklaushev VP, Xiong S, Chekhonin VP, Peltzer K, Wang G, Zhang C. Advanced Hepatocellular Carcinoma with Bone Metastases: Prevalence, Associated Factors, and Survival Estimation. Med Sci Monit 2019;25:1105-12. [PMID: 30739123 DOI: 10.12659/MSM.913470] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
587 Lorente L, Rodriguez ST, Sanz P, Abreu-González P, Díaz D, Moreno AM, Borja E, Martín MM, Jiménez A, Barrera MA. Association between Pre-Transplant Serum Malondialdehyde Levels and Survival One Year after Liver Transplantation for Hepatocellular Carcinoma. Int J Mol Sci 2016;17:500. [PMID: 27058525 DOI: 10.3390/ijms17040500] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
588 Stallone G, Infante B, Grandaliano G. Management and prevention of post-transplant malignancies in kidney transplant recipients. Clin Kidney J 2015;8:637-44. [PMID: 26413294 DOI: 10.1093/ckj/sfv054] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
589 Ren A, Li Z, Zhang X, Deng R, Ma Y. Inflammation-Based Prognostic Scores in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma After Liver Transplantation. J Hepatocell Carcinoma 2020;7:101-6. [PMID: 32766175 DOI: 10.2147/JHC.S259992] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
590 Ringelhan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci. 2017;372. [PMID: 28893941 DOI: 10.1098/rstb.2016.0274] [Cited by in Crossref: 100] [Cited by in F6Publishing: 79] [Article Influence: 33.3] [Reference Citation Analysis]
591 Xie F, Zang J, Guo X, Xu F, Shen R, Yan L, Yang J, He J. Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2012;138:455-62. [DOI: 10.1007/s00432-011-1117-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
592 Nevarez NM, Yopp AC. Challenging the Treatment Paradigm: Selecting Patients for Surgical Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Hepatocell Carcinoma 2021;8:851-60. [PMID: 34350140 DOI: 10.2147/JHC.S291530] [Reference Citation Analysis]
593 Delis SG, Dervenis C. Selection criteria for liver resection in patients with hepatocellular carcinoma and chronic liver disease. World J Gastroenterol. 2008;14:3452-3460. [PMID: 18567070 DOI: 10.3748/wjg.14.3452] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
594 Nguyen K, Jack K, Sun W. Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy. Diseases 2015;4:E1. [PMID: 28933381 DOI: 10.3390/diseases4010001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
595 Kotewall CN, Cheung TT, She WH, Ma KW, Tsang SHY, Dai JWC, Chan ACY, Chok KSH, Lo CM. The role of radiofrequency ablation to liver transection surface in patients with close tumor margin of HCC during hepatectomy-a case matched study. Transl Gastroenterol Hepatol 2017;2:33. [PMID: 28529987 DOI: 10.21037/tgh.2017.03.19] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
596 Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, Sanchez W, Roberts JP, Yao FY. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot". Transplantation. 2017;101:2071-2078. [PMID: 28353492 DOI: 10.1097/tp.0000000000001752] [Cited by in Crossref: 38] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
597 Na GH, Hong TH, You YK, Kim DG. Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation. World J Gastroenterol 2016;22:5790-9. [PMID: 27433092 DOI: 10.3748/wjg.v22.i25.5790] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
598 Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, Lok AS, Lee WM. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol. 2013;108:425-432. [PMID: 23337478 DOI: 10.1038/ajg.2012.449] [Cited by in Crossref: 133] [Cited by in F6Publishing: 121] [Article Influence: 16.6] [Reference Citation Analysis]
599 Kim BH, Park JW. Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation. J Korean Med Sci 2018;33:e286. [PMID: 30402051 DOI: 10.3346/jkms.2018.33.e286] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
600 Van Ha TG. Transarterial chemoembolization for hepatocellular carcinoma. Semin Intervent Radiol 2009;26:270-5. [PMID: 21326572 DOI: 10.1055/s-0029-1225672] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
601 Chen XP, Huang ZY. Surgical treatment of hepatocellular carcinoma in China: surgical techniques, indications, and outcomes. Langenbecks Arch Surg. 2005;390:259-265. [PMID: 15875211 DOI: 10.1007/s00423-005-0552-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
602 Cárdenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE, Henderson MA, Schefter TE, Tudor K, Deluca J. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol. 2010;12:218-225. [PMID: 20231127 DOI: 10.1007/s12094-010-0492-x] [Cited by in Crossref: 196] [Cited by in F6Publishing: 153] [Article Influence: 17.8] [Reference Citation Analysis]
603 Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol. 2017;3:493-500. [PMID: 27838698 DOI: 10.1001/jamaoncol.2016.5116] [Cited by in Crossref: 111] [Cited by in F6Publishing: 95] [Article Influence: 27.8] [Reference Citation Analysis]
604 Venook AP. Hepatocellular carcinoma. Curr Treat Options Oncol. 2000;1:407-415. [PMID: 12057148 DOI: 10.1007/s11864-000-0068-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
605 Clavien PA. Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann Surg. 2007;245:843-845. [PMID: 17522507 DOI: 10.1097/sla.0b013e31805d0788] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
606 Bakr S, Echegaray S, Shah R, Kamaya A, Louie J, Napel S, Kothary N, Gevaert O. Noninvasive radiomics signature based on quantitative analysis of computed tomography images as a surrogate for microvascular invasion in hepatocellular carcinoma: a pilot study. J Med Imaging (Bellingham) 2017;4:041303. [PMID: 28840174 DOI: 10.1117/1.JMI.4.4.041303] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
607 Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, Schipper MJ, Feng M. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. J Clin Oncol. 2016;34:452-459. [PMID: 26628466 DOI: 10.1200/jco.2015.61.4925] [Cited by in Crossref: 259] [Cited by in F6Publishing: 95] [Article Influence: 43.2] [Reference Citation Analysis]
608 Schwartz JM, Ham JM. Treatment of Hepatocellular Carcinoma. Curr Treat Options Gastroenterol 2003;6:465-72. [PMID: 14585235 DOI: 10.1007/s11938-003-0048-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
609 Robinson A, Tavakoli H, Liu B, Bhuket T, Wong RJ. Advanced Hepatocellular Carcinoma Tumor Stage at Diagnosis in the 1945-1965 Birth Cohort Reflects Poor Use of Hepatocellular Carcinoma Screening. Hepatol Commun 2018;2:1147-55. [PMID: 30202827 DOI: 10.1002/hep4.1236] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
610 Bhatia R, Ravulapati S, Befeler A, Dombrowski J, Gadani S, Poddar N. Hepatocellular Carcinoma with Bone Metastases: Incidence, Prognostic Significance, and Management-Single-Center Experience. J Gastrointest Cancer 2017;48:321-5. [PMID: 28891006 DOI: 10.1007/s12029-017-9998-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
611 Sung MJ, Jo JH, Lee HS, Park JY, Bang S, Park SW, Song SY, Joo DJ, Chung MJ. Optimal drainage of anastomosis stricture after living donor liver transplantation. Surg Endosc 2021. [PMID: 33796905 DOI: 10.1007/s00464-021-08456-4] [Reference Citation Analysis]
612 Ganschow R, Pollok JM, Jankofsky M, Junge G. The role of everolimus in liver transplantation. Clin Exp Gastroenterol. 2014;7:329-343. [PMID: 25214801 DOI: 10.2147/ceg.s41780] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 3.6] [Reference Citation Analysis]
613 Hu J, Wang Z, Fan J, Dai Z, He YF, Qiu SJ, Huang XW, Sun J, Xiao YS, Song K, Shi YH, Sun QM, Yang XR, Shi GM, Yu L, Yang GH, Ding ZB, Gao Q, Tang ZY, Zhou J. Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after liver transplantation. PLoS One 2011;6:e26003. [PMID: 21998744 DOI: 10.1371/journal.pone.0026003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
614 Takamura H, Nakanuma S, Hayashi H, Tajima H, Kakinoki K, Sakai S, Makino I, Nakagawara H, Miyashita T, Okamoto K, Nakamura K, Oyama K, Inokuchi M, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Ohnishi I, Kayahara M, Tani T, Arai K, Yamashita T, Yamashita T, Kitamura H, Ikeda H, Kaneko S, Nakanuma Y, Matsui O, Ohta T. Evaluation of eligibility criteria in living donor liver transplantation for hepatocellular carcinoma by α-SMA-positive cancer-associated fibroblasts. Oncol Rep 2013;30:1561-74. [PMID: 23863893 DOI: 10.3892/or.2013.2616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
615 Rong G, Bai W, Dong Z, Wang C, Lu Y, Zeng Z, Qu J, Lou M, Wang H, Gao X, Chang X, An L, Li H, Chen Y, Hu KQ, Yang Y. Long-term outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria. PLoS One. 2015;10:e0123065. [PMID: 25849963 DOI: 10.1371/journal.pone.0123065] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
616 Jalbani IK, Nazim SM, Tariq MU, Abbas F. Adrenalectomy for solitary metastasis of Hepatocellular carcinoma post liver transplantation: Case report and literature review. Pak J Med Sci 2016;32:1044-6. [PMID: 27648064 DOI: 10.12669/pjms.324.10339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
617 Bolondi L, Gramantieri L. From liver cirrhosis to HCC. Intern Emerg Med 2011;6 Suppl 1:93-8. [PMID: 22009618 DOI: 10.1007/s11739-011-0682-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
618 Pande SB, Doval DC, Pavithran K, Sharma JB, Shirali R, Jena A. Gemcitabine and cisplatin-based combination chemotherapy in advanced hepatocellular carcinoma: An Indian experience. Indian J Med Paediatr Oncol 2012;33:42-7. [PMID: 22754208 DOI: 10.4103/0971-5851.96968] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
619 Rahimi R, Yopp A, Singal A. Current issues and future trends in surveillance for hepatocellular carcinoma. Clin Liver Disease. 2012;1:186-189. [PMID: 31186884 DOI: 10.1002/cld.115] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
620 Patel SS, Arrington AK, McKenzie S, Mailey B, Ding M, Lee W, Artinyan A, Nissen N, Colquhoun SD, Kim J. Milan Criteria and UCSF Criteria: A Preliminary Comparative Study of Liver Transplantation Outcomes in the United States. Int J Hepatol. 2012;2012:253517. [PMID: 22957260 DOI: 10.1155/2012/253517] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
621 Tralhão JG, Hoti E, Oliveiros B, Abrantes AM, Botelho MF, Castro-Sousa F. Intermittent pringle maneuver and hepatic function: perioperative monitoring by noninvasive ICG-clearance. World J Surg 2009;33:2627-34. [PMID: 19760319 DOI: 10.1007/s00268-009-0204-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
622 Zarrinpar A, Busuttil RW. Liver transplantation: past, present and future. Nat Rev Gastroenterol Hepatol. 2013;10:434-440. [PMID: 23752825 DOI: 10.1038/nrgastro.2013.88] [Cited by in Crossref: 104] [Cited by in F6Publishing: 73] [Article Influence: 13.0] [Reference Citation Analysis]
623 Mazzaferro V. Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach. Hepatology. 2016;63:1707-1717. [PMID: 26703761 DOI: 10.1002/hep.28420] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 13.2] [Reference Citation Analysis]
624 Cabibbo G, Maida M, Genco C, Alessi N, Peralta M, Butera G, Galia M, Brancatelli G, Genova C, Raineri M, Orlando E, Attardo S, Giarratano A, Midiri M, Di Marco V, Craxì A, Cammà C. Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response. PLoS One 2013;8:e70016. [PMID: 23922893 DOI: 10.1371/journal.pone.0070016] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
625 Nejatollahi SMR, Marashi SA, Janatmakan F, Vosoghian M, Hasanzadehkiabi M, Fazel I. A Single-Center Report on Liver Transplantation: First Experiences from Shahid Beheshti University of Medical Sciences. Middle East J Dig Dis 2020;12:252-6. [PMID: 33564382 DOI: 10.34172/mejdd.2020.190] [Reference Citation Analysis]
626 Wang J, Wang F, Kessinger A. Outcome of Combined Hepatocellular and Cholangiocarcinoma of the Liver. J Oncol. 2010;2010:1-7. [PMID: 20871663 DOI: 10.1155/2010/917356] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
627 Wilder JM, Oloruntoba OO, Muir AJ, Moylan CA. Role of patient factors, preferences, and distrust in health care and access to liver transplantation and organ donation. Liver Transpl 2016;22:895-905. [PMID: 27027394 DOI: 10.1002/lt.24452] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
628 Hernandez-Alejandro R, Croome KP, Drage M, Sela N, Parfitt J, Chandok N, Marotta P, Dale C, Wall W, Quan D. A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma. World J Gastroenterol. 2012;18:4145-4149. [PMID: 22919246 DOI: 10.3748/wjg.v18.i31.4145] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
629 Elshamy M, Aucejo F, Menon KV, Eghtesad B. Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria. World J Hepatol 2016;8:874-80. [PMID: 27478537 DOI: 10.4254/wjh.v8.i21.874] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
630 Wei Q, Xu X, Wang C, Zhuang R, Zhuang L, Zhou L, Xie H, Wu J, Zhang M, Shen Y, Wang W, Zheng S. Efficacy and Safety of a Steroid-Free Immunosuppressive Regimen after Liver Transplantation for Hepatocellular Carcinoma. Gut Liver 2016;10:604-10. [PMID: 27074818 DOI: 10.5009/gnl15017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
631 Nissen NN, Menon V, Bresee C, Tran TT, Annamalai A, Poordad F, Fair JH, Klein AS, Boland B, Colquhoun SD. Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient. HPB (Oxford). 2011;13:626-632. [PMID: 21843263 DOI: 10.1111/j.1477-2574.2011.00342.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
632 Ziogas IA, Tsoulfas G. Evolving role of Sorafenib in the management of hepatocellular carcinoma. World J Clin Oncol. 2017;8:203-213. [PMID: 28638790 DOI: 10.5306/wjco.v8.i3.203] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
633 Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, Lurje G. Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach. Int J Mol Sci 2019;20:E1465. [PMID: 30909504 DOI: 10.3390/ijms20061465] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 22.5] [Reference Citation Analysis]
634 Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, de Jong KP, Duvoux C, Kneteman NM, Adam R. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer. 2010;10:190. [PMID: 20459775 DOI: 10.1186/1471-2407-10-190] [Cited by in Crossref: 118] [Cited by in F6Publishing: 93] [Article Influence: 10.7] [Reference Citation Analysis]
635 Serper M, Taddei TH, Mehta R, D'Addeo K, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, Goldberg DS, Valderrama A, Kaplan DE; VOCAL Study Group. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. Gastroenterology. 2017;152:1954-1964. [PMID: 28283421 DOI: 10.1053/j.gastro.2017.02.040] [Cited by in Crossref: 94] [Cited by in F6Publishing: 76] [Article Influence: 23.5] [Reference Citation Analysis]
636 Orcutt ST, Anaya DA. Liver Resection and Surgical Strategies for Management of Primary Liver Cancer. Cancer Control 2018;25:1073274817744621. [PMID: 29327594 DOI: 10.1177/1073274817744621] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 16.3] [Reference Citation Analysis]
637 Panda D. Role of surveillance in prevention of hepatocellular carcinoma. J Clin Exp Hepatol 2014;4:S43-9. [PMID: 25755610 DOI: 10.1016/j.jceh.2014.03.044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
638 Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2018;18:1206-1213. [PMID: 29068145 DOI: 10.1111/ajt.14549] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
639 Hwang S, Kim Y, Kim DK, Ahn C, Moon D, Kim K, Ha T, Song G, Jung D, Kim HR, Park G, Namgoong J, Yoon S, Jung S, Park SI, Lee S. Resection of Pulmonary Metastases from Hepatocellular Carcinoma following Liver Transplantation. World J Surg 2012;36:1592-602. [DOI: 10.1007/s00268-012-1533-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
640 Clift AK, Frilling A. Liver transplantation and multivisceral transplantation in the management of patients with advanced neuroendocrine tumours. World J Gastroenterol. 2018;24:2152-2162. [PMID: 29853733 DOI: 10.3748/wjg.v24.i20.2152] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
641 Feng J, Wu J, Zhu R, Feng D, Yu L, Zhang Y, Bu D, Li C, Zhou Y, Si L, Liu Y, Liang Z, Xu J, Wu T. Simple Risk Score for Prediction of Early Recurrence of Hepatocellular Carcinoma within the Milan Criteria after Orthotopic Liver Transplantation. Sci Rep. 2017;7:44036. [PMID: 28276470 DOI: 10.1038/srep44036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
642 Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, Samuel D, Bismuth H. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: A reasonable strategy? Ann Surg. 2003;238:508-18; discussion 518-9. [PMID: 14530722 DOI: 10.1097/01.sla.0000090449.87109.44] [Cited by in Crossref: 66] [Cited by in F6Publishing: 128] [Article Influence: 3.7] [Reference Citation Analysis]
643 Torimura T, Iwamoto H. Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects. Clin Mol Hepatol 2021;27:236-45. [PMID: 33317248 DOI: 10.3350/cmh.2020.0204] [Reference Citation Analysis]
644 Elsayes KM, Kielar AZ, Agrons MM, Szklaruk J, Tang A, Bashir MR, Mitchell DG, Do RK, Fowler KJ, Chernyak V, Sirlin CB. Liver Imaging Reporting and Data System: an expert consensus statement.J Hepatocell Carcinoma. 2017;4:29-39. [PMID: 28255543 DOI: 10.2147/JHC.S125396] [Cited by in Crossref: 29] [Cited by in F6Publishing: 9] [Article Influence: 7.3] [Reference Citation Analysis]
645 Salsamendi J, Pereira K, Kang K, Fan J. Minimally invasive percutaneous endovascular therapies in the management of complications of non-alcoholic fatty liver disease (NAFLD): A case report. J Radiol Case Rep 2015;9:36-43. [PMID: 26629307 DOI: 10.3941/jrcr.v9i9.2557] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
646 Kornberg A, Witt U, Schernhammer M, Kornberg J, Ceyhan GO, Mueller K, Friess H, Thrum K. Combining 18F-FDG positron emission tomography with Up-to-seven criteria for selecting suitable liver transplant patients with advanced hepatocellular carcinoma. Sci Rep. 2017;7:14176. [PMID: 29074969 DOI: 10.1038/s41598-017-14430-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
647 Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21:266-280. [PMID: 18628926 DOI: 10.1080/08998280.2008.11928410] [Cited by in Crossref: 105] [Cited by in F6Publishing: 94] [Article Influence: 10.5] [Reference Citation Analysis]
648 Belghiti J, Kianmanesh R. Surgical treatment of hepatocellular carcinoma. HPB (Oxford). 2005;7:42-49. [PMID: 18333160 DOI: 10.1080/13651820410024067] [Cited by in Crossref: 81] [Cited by in F6Publishing: 66] [Article Influence: 7.4] [Reference Citation Analysis]
649 Congly SE, Doucette KE, Coffin CS. Outcomes and management of viral hepatitis and human immunodeficiency virus co-infection in liver transplantation. World J Gastroenterol 2014;20:414-24. [PMID: 24574710 DOI: 10.3748/wjg.v20.i2.414] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
650 Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Itobayashi E, Nouso K, Kariyama K, Ishikawa T, Hirooka M, Hiasa Y. Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan. Cancer Sci. 2017;108:1414-1420. [PMID: 28406546 DOI: 10.1111/cas.13257] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
651 Yamazaki S, Takayama T. Surgical treatment of hepatocellular carcinoma: evidence-based outcomes. World J Gastroenterol. 2008;14:685-692. [PMID: 18205256 DOI: 10.3748/wjg.14.685] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
652 Lai Q, Melandro F, Pinheiro RS, Donfrancesco A, Fadel BA, Levi Sandri GB, Rossi M, Berloco PB, Frattaroli FM. Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again. Int J Hepatol. 2012;2012:893103. [PMID: 22792474 DOI: 10.1155/2012/893103] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
653 Al Sibae MR, Cappell MS. Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS. Dig Dis Sci. 2011;56:977-987. [PMID: 20844956 DOI: 10.1007/s10620-010-1390-3] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
654 Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Eguchi S, Yamashita T, Kudo M. Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan. Liver Cancer 2019;8:403-11. [PMID: 31768348 DOI: 10.1159/000495944] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
655 Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11-e22. [PMID: 22047762 DOI: 10.1016/s1470-2045(1170175-9] [Reference Citation Analysis]
656 Bednarsch J, Czigany Z, Heise D, Joechle K, Luedde T, Heij L, Bruners P, Ulmer TF, Neumann UP, Lang SA. Prognostic evaluation of HCC patients undergoing surgical resection: an analysis of 8 different staging systems. Langenbecks Arch Surg. 2021;406:75-86. [PMID: 33294952 DOI: 10.1007/s00423-020-02052-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
657 Li HY, Wei YG, Yan LN, Li B. Salvage liver transplantation in the treatment of hepatocellular carcinoma: a meta-analysis. World J Gastroenterol. 2012;18:2415-2422. [PMID: 22654435 DOI: 10.3748/wjg.v18.i19.2415] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
658 Otto G, Heuschen U, Hofmann WJ, Krumm G, Hinz U, Herfarth C. Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis. Ann Surg. 1998;227:424-432. [PMID: 9527066 DOI: 10.1097/00000658-199803000-00015] [Cited by in Crossref: 176] [Cited by in F6Publishing: 167] [Article Influence: 7.7] [Reference Citation Analysis]
659 Jakobs TF, Hoffmann RT, Tatsch K, Trumm C, Reiser MF. [Therapy response of liver tumors after selective internal radiation therapy]. Radiologe. 2008;48:839-849. [PMID: 18766324 DOI: 10.1007/s00117-008-1730-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
660 Parikh AA, Gentner B, Wu TT, Curley SA, Ellis LM, Vauthey JN. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg. 2003;7:1082-1088. [PMID: 14675719 DOI: 10.1097/00000658-200205000-00015] [Cited by in Crossref: 137] [Cited by in F6Publishing: 126] [Article Influence: 8.1] [Reference Citation Analysis]
661 Kim DY, Kwon DS, Salem R, Ma CK, Abouljoud MS. Successful embolization of hepatocelluar carcinoma with yttrium-90 glass microspheres prior to liver transplantation. J Gastrointest Surg. 2006;10:413-416. [PMID: 16504888 DOI: 10.1016/j.gassur.2005.06.019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
662 Waghray A, Murali AR, Menon KN. Hepatocellular carcinoma: From diagnosis to treatment. World J Hepatol. 2015;7:1020-1029. [PMID: 26052391 DOI: 10.4254/wjh.v7.i8.1020] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 13.0] [Reference Citation Analysis]
663 Xie QY, Almudevar A, Whitney-Miller CL, Barry CT, McCall MN. A microRNA biomarker of hepatocellular carcinoma recurrence following liver transplantation accounting for within-patient heterogeneity. BMC Med Genomics 2016;9:18. [PMID: 27059462 DOI: 10.1186/s12920-016-0179-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
664 Shields A, Reddy KR. Hepatocellular carcinoma: current treatment strategies. Curr Treat Options Gastroenterol 2005;8:457-66. [PMID: 16313863 DOI: 10.1007/s11938-005-0032-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
665 Tohyama T, Sakamoto K, Tamura K, Nakamura T, Watanabe J, Wakisaka H, Takada Y. Pharyngeal metastasis following living-donor liver transplantation for hepatocellular carcinoma: a case report and literature review. World J Surg Oncol 2020;18:109. [PMID: 32466780 DOI: 10.1186/s12957-020-01873-0] [Reference Citation Analysis]
666 Han ZB, Zhong L, Teng MJ, Fan JW, Tang HM, Wu JY, Chen HY, Wang ZW, Qiu GQ, Peng ZH. Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. Mol Oncol. 2012;6:445-457. [PMID: 22552153 DOI: 10.1016/j.molonc.2012.04.001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 7.7] [Reference Citation Analysis]
667 Ishikawa T. Strategy for improving survival and reducing recu